The	O
macrophage	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
directs	O
tissue-specific	O
expression	O
of	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
receptor	I-protein
.	O

The	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	I-protein
is	O
expressed	O
in	O
a	O
tissue-specific	O
fashion	O
from	O
two	O
distinct	O
promoters	B-DNA
in	O
monocytes/macrophages	B-cell_type
and	O
the	O
placenta	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	B-cell_type
progenitors	I-cell_type
to	O
the	O
monocyte/macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M-CSF	B-protein
receptor	I-protein
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
monocytic	I-DNA
M-CSF	I-DNA
receptor	I-DNA
promoter	I-DNA
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue-specific	O
fashion	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	B-protein
factors	I-protein
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	B-DNA
genes	I-DNA
is	O
the	O
macrophage-	B-protein
and	I-protein
B-cell-specific	I-protein
PU.1	I-protein
transcription	B-protein
factor	I-protein
,	O
we	O
investigated	O
whether	O
PU.1	B-protein
binds	O
and	O
activates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro-translated	B-protein
PU.1	I-protein
and	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
just	O
upstream	O
from	O
the	O
major	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O

Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU.1	B-protein
binding	O
decrease	O
M-CSF	B-protein
receptor	I-protein
promoter	O
activity	O
significantly	O
in	O
macrophage	B-cell_line
cell	I-cell_line
lines	I-cell_line
only	O
.	O

Furthermore	O
,	O
PU.1	B-protein
transactivates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
in	O
nonmacrophage	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
PU.1	B-protein
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	B-protein
macrophage	I-protein
growth	I-protein
factor	I-protein
.	O

MoLrECcULar	NULL
aAnp	NULL
CELLULAR	NULL
BIOLOGY	NULL
,	NULL
Jan.	NULL
1994	NULL
,	NULL
p.	NULL
373-381	NULL
0270-7306/94/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
Â©	NULL
1994	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

14	NULL
,	NULL
No	NULL
.	NULL

1	NULL
The	NULL
Macrophage	NULL
Transcription	NULL
Factor	NULL
PU.1	NULL
Directs	NULL
Tissue-Specific	NULL
Expression	NULL
of	NULL
the	NULL
Macrophage	NULL
Colony-Stimulating	NULL
Factor	NULL
Receptor	NULL
DONG-ER	NULL
ZHANG	NULL
,	NULL
CHRISTOPHER	NULL
J.	NULL
HETHERINGTON	NULL
,	NULL
HUI-MIN	NULL
CHEN	NULL
,	NULL
anp	NULL
DANIEL	NULL
G.	NULL
TENEN*	NULL
Division	NULL
of	NULL
Hematology/Oncology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
and	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
Received	NULL
12	NULL
July	NULL
1993/Returned	NULL
for	NULL
modification	NULL
26	NULL
August	NULL
1993/Accepted	NULL
22	NULL
September	NULL
1993	NULL
The	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
M-CSF	NULL
)	NULL
receptor	NULL
is	NULL
expressed	NULL
in	NULL
a	NULL
tissue-specific	NULL
fashion	NULL
from	NULL
two	NULL
distinct	NULL
promoters	NULL
in	NULL
monocytes/macrophages	NULL
and	NULL
the	NULL
placenta	NULL
.	NULL

In	NULL
order	NULL
to	NULL
further	NULL
understand	NULL
the	NULL
transcription	NULL
factors	NULL
which	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
commitment	NULL
of	NULL
multipotential	NULL
progenitors	NULL
to	NULL
the	NULL
monocyte/	NULL
macrophage	NULL
lineage	NULL
,	NULL
we	NULL
have	NULL
initiated	NULL
an	NULL
investigation	NULL
of	NULL
the	NULL
factors	NULL
which	NULL
activate	NULL
the	NULL
M-CSF	NULL
receptor	NULL
very	NULL
early	NULL
during	NULL
the	NULL
monocyte	NULL
differentiation	NULL
process	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
human	NULL
monocytic	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
directs	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
a	NULL
tissue-specific	NULL
fashion	NULL
.	NULL

Since	NULL
one	NULL
of	NULL
the	NULL
few	NULL
transcription	NULL
factors	NULL
which	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
monocyte	NULL
genes	NULL
is	NULL
the	NULL
macrophage-	NULL
and	NULL
B-cell-specific	NULL
PU.1	NULL
transcription	NULL
factor	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
PU.1	NULL
binds	NULL
and	NULL
activates	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
both	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
and	NULL
PU.1	NULL
from	NULL
nuclear	NULL
extracts	NULL
bind	NULL
to	NULL
a	NULL
specific	NULL
site	NULL
in	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
just	NULL
upstream	NULL
from	NULL
the	NULL
major	NULL
transcription	NULL
initiation	NULL
site	NULL
.	NULL

Mutations	NULL
in	NULL
this	NULL
site	NULL
which	NULL
eliminate	NULL
PU.1	NULL
binding	NULL
decrease	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
activity	NULL
significantly	NULL
in	NULL
macrophage	NULL
cell	NULL
lines	NULL
only	NULL
.	NULL

Furthermore	NULL
,	NULL
PU.1	NULL
transactivates	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
in	NULL
nonmacrophage	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
PU.1	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
macrophage	NULL
gene	NULL
regulation	NULL
and	NULL
development	NULL
by	NULL
directing	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
receptor	NULL
for	NULL
a	NULL
key	NULL
macrophage	NULL
growth	NULL
factor	NULL
.	NULL

The	NULL
150-kDa	NULL
receptor	NULL
of	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
M-CSF	NULL
)	NULL
receptor	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
c-fms	NULL
proto-oncogene	NULL
,	NULL
the	NULL
cellular	NULL
counterpart	NULL
of	NULL
the	NULL
Susan	NULL
McDonough	NULL
strain	NULL
of	NULL
the	NULL
feline	NULL
sarcoma	NULL
virus	NULL
v-fms	NULL
gene	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
M-CSF	NULL
receptor	NULL
is	NULL
an	NULL
integral	NULL
transmembrane	NULL
glycoprotein	NULL
with	NULL
an	NULL
intracellular	NULL
tyrosine	NULL
kinase	NULL
domain	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
precise	NULL
mechanism	NULL
of	NULL
intracellular	NULL
signalling	NULL
produced	NULL
by	NULL
the	NULL
M-CSF	NULL
receptor	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
characterized	NULL
.	NULL

However	NULL
,	NULL
many	NULL
experiments	NULL
have	NULL
demonstrated	NULL
that	NULL
it	NULL
is	NULL
required	NULL
for	NULL
the	NULL
differentiation	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
survival	NULL
of	NULL
monocytic	NULL
phagocytes	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Point	NULL
mutations	NULL
in	NULL
the	NULL
extracellular	NULL
domain	NULL
enable	NULL
the	NULL
receptor	NULL
to	NULL
convert	NULL
NIH	NULL
3T3	NULL
cells	NULL
to	NULL
transformed	NULL
tumorigenic	NULL
cells	NULL
(	NULL
30	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
same	NULL
point	NULL
mutations	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
and	NULL
myelodysplasia	NULL
,	NULL
diseases	NULL
characterized	NULL
by	NULL
the	NULL
failure	NULL
of	NULL
differentiation	NULL
of	NULL
monocytic	NULL
precursors	NULL
(	NULL
27	NULL
,	NULL
39	NULL
)	NULL
.	NULL

In	NULL
humans	NULL
,	NULL
the	NULL
M-CSF	NULL
receptor	NULL
gene	NULL
is	NULL
located	NULL
on	NULL
chromosome	NULL
5	NULL
at	NULL
band	NULL
5q33.3	NULL
,	NULL
and	NULL
deletions	NULL
of	NULL
this	NULL
region	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
some	NULL
cases	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
(	NULL
18	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
mutations	NULL
in	NULL
the	NULL
coding	NULL
region	NULL
,	NULL
alterations	NULL
in	NULL
expression	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
affect	NULL
macrophage	NULL
development	NULL
.	NULL

The	NULL
integration	NULL
of	NULL
Friend	NULL
murine	NULL
leukemia	NULL
virus	NULL
into	NULL
the	NULL
5	NULL
end	NULL
of	NULL
the	NULL
murine	NULL
M-CSF	NULL
receptor	NULL
gene	NULL
results	NULL
in	NULL
the	NULL
high	NULL
expression	NULL
of	NULL
a	NULL
normal-sized	NULL
receptor	NULL
and	NULL
can	NULL
induce	NULL
murine	NULL
myeloblastic	NULL
leukemia	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
normal	NULL
tissues	NULL
,	NULL
M-CSF	NULL
receptor	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
monocytes/macrophages	NULL
and	NULL
placental	NULL
trophoblast	NULL
cells	NULL
(	NULL
35	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
its	NULL
expression	NULL
differs	NULL
between	NULL
these	NULL
two	NULL
tissues	NULL
(	NULL
28	NULL
,	NULL
29	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Different	NULL
promoters	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
,	NULL
330	NULL
Brookline	NULL
Ave.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02215	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
617	NULL
)	NULL
735-5561	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
617	NULL
)	NULL
735-3299	NULL
.	NULL

373	NULL
direct	NULL
M-CSF	NULL
receptor	NULL
tissue-specific	NULL
expression	NULL
in	NULL
the	NULL
two	NULL
different	NULL
tissues	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
monocytes	NULL
,	NULL
transcription	NULL
initiates	NULL
at	NULL
multiple	NULL
sites	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
start	NULL
codon	NULL
ATG	NULL
.	NULL

In	NULL
placental	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
transcription	NULL
starts	NULL
26	NULL
kb	NULL
upstream	NULL
and	NULL
includes	NULL
an	NULL
additional	NULL
noncoding	NULL
exon	NULL
.	NULL

M-CSF	NULL
receptor	NULL
expression	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
very	NULL
early	NULL
stages	NULL
of	NULL
myeloid	NULL
differentiation	NULL
and	NULL
increases	NULL
dramatically	NULL
during	NULL
this	NULL
differentiation	NULL
process	NULL
(	NULL
7	NULL
,	NULL
11	NULL
,	NULL
32	NULL
)	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
expression	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
cited	NULL
above	NULL
,	NULL
suggests	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
receptor	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
the	NULL
process	NULL
of	NULL
monocytic	NULL
differentiation	NULL
.	NULL

However	NULL
,	NULL
the	NULL
transcription	NULL
factors	NULL
directing	NULL
the	NULL
differentiation	NULL
of	NULL
pluripotential	NULL
progenitor	NULL
cells	NULL
to	NULL
the	NULL
monocytic	NULL
lineage	NULL
are	NULL
still	NULL
poorly	NULL
understood	NULL
.	NULL

The	NULL
ets	NULL
family	NULL
member	NULL
PU.1	NULL
was	NULL
originally	NULL
isolated	NULL
as	NULL
the	NULL
Spi-1	NULL
oncogene	NULL
,	NULL
in	NULL
which	NULL
its	NULL
overexpression	NULL
in	NULL
early	NULL
erythroid	NULL
cells	NULL
blocked	NULL
erythro-blast	NULL
differentiation	NULL
(	NULL
17	NULL
,	NULL
34	NULL
)	NULL
.	NULL

PU.1	NULL
is	NULL
specifically	NULL
expressed	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
monocytes	NULL
(	NULL
15	NULL
)	NULL
.	NULL

In	NULL
B	NULL
cells	NULL
,	NULL
PU.1	NULL
recruits	NULL
a	NULL
second	NULL
B-cell-specific	NULL
DNA	NULL
binding	NULL
factor	NULL
(	NULL
NF-EMS	NULL
)	NULL
to	NULL
a	NULL
site	NULL
important	NULL
for	NULL
immunoglobulin	NULL
xk	NULL
3	NULL
'	NULL
enhancer	NULL
activity	NULL
(	NULL
24	NULL
)	NULL
,	NULL
and	NULL
phosphorylation	NULL
of	NULL
a	NULL
specific	NULL
serine	NULL
residue	NULL
(	NULL
Ser-148	NULL
)	NULL
in	NULL
PU.1	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
interaction	NULL
between	NULL
PU.1	NULL
and	NULL
NF-EMS	NULL
(	NULL
25	NULL
)	NULL
.	NULL

In	NULL
monocytes	NULL
,	NULL
PU.1	NULL
binding	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
myeloid-cell-specific	NULL
expression	NULL
of	NULL
CD11b	NULL
(	NULL
MAC-1	NULL
receptor	NULL
alpha	NULL
chain	NULL
)	NULL
,	NULL
a	NULL
gene	NULL
expressed	NULL
late	NULL
during	NULL
the	NULL
course	NULL
of	NULL
monocytic	NULL
differentiation	NULL
(	NULL
22	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
mechanism	NULL
of	NULL
M-CSF	NULL
receptor	NULL
monocyte-specific	NULL
expression	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
function	NULL
of	NULL
PU.1	NULL
on	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
activity	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
PU.1	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
the	NULL
monocytic	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
M-CSF	NULL
receptor	NULL
and	NULL
suggest	NULL
that	NULL
PU.1	NULL
may	NULL
therefore	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
monocyte	NULL
development	NULL
.	NULL

374	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

-	NULL
416	NULL
L	NULL
Entron	NULL
1	NULL
(	NULL
26	NULL
kb	NULL
)	NULL
...	NULL
AAATAATAAT	NULL
AAXTAAATTTT	NULL
TAAAAGATAT	NULL
GCATTACTTT	NULL
-401	NULL
-E-	NULL
GGAGATTCCA	NULL
AGGATTTTAG	NULL
GAGTTGTAAG	NULL
CCAGGACATC	NULL
AGGGTAAAGA	NULL
AAXAAATATAT	NULL
ATGTCACAXT	NULL
ATCATGCAAC	NULL
CTAACTTCTC	NULL
TTTGGGATCT	NULL
-301	NULL
GCCAGAGCCA	NULL
CCTGATCACT	NULL
CTGAAGACCC	NULL
TCATTTGTGC	NULL
TACTGACTAA	NULL
CGGTCTGGCT	NULL
GCTCTTGGAC	NULL
ATGTCTCTTC	NULL
TCCCAAGACC	NULL
CCTTGAAGAT	NULL
-201	NULL
GGCTTTAGAA	NULL
GGGCCCCAAA	NULL
CTTAGCTAGC	NULL
TCCCCCCAAG	NULL
CTCAGGCTGG	NULL
CCCTGCCCCA	NULL
GACTGCGACC	NULL
CCTCCCTCTT	NULL
GGGTTCAAGG	NULL
CTTTGTTTTC	NULL
-101	NULL
Exon	NULL
2	NULL
AA	NULL
AMGGGGAAGA	NULL
AGAGGATCAG	NULL
CCCAAGGAGG	NULL
AGGAAGAGGA	NULL
AMACAAGACA	NULL
-1	NULL
Minin	NULL
PU.1	NULL
+11	NULL
PU.1	NULL
PU.1	NULL
AACAGCCAGT	NULL
GCAGAGGAGA	NULL
GGAACGTGTG	NULL
TCCAGIGTCC	NULL
CGATCCCTGC	NULL
GGAGCTAGTA	NULL
GCTGAGAGCT	NULL
CTGTGCCCTG	NULL
GGCACCTTGC	NULL
AGCCCTGCAC	NULL
+100	NULL
PU.1	NULL
Exon	NULL
2	NULL
CTGCCTGCCA	NULL
CTTCCCCACC	NULL
GAGGCCATGG	NULL
GCCCAGGAGT	NULL
TCTGCTGCTC	NULL
CTGCTGGTGG	NULL
CCACAGCTTG	NULL
GCAT	NULL
MO	NULL
G	NULL
P	NULL
G	NULL
V	NULL
L	NULL
L	NULL
L	NULL
L	NULL
L	NULL
V	NULL
A	NULL
T	NULL
A	NULL
Wo	NULL
H	NULL
TTCTTAAAGA	NULL
CCCAAGATTT	NULL
CCAAACTCTG	NULL
TGGTTGCCTT	NULL
GCCT	NULL
.	NULL

AAG	NULL
A	NULL
...	NULL
Intron	NULL
2	NULL
+124	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Map	NULL
and	NULL
5	NULL
'	NULL
flanking	NULL
sequence	NULL
of	NULL
the	NULL
human	NULL
monocytic	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
.	NULL

The	NULL
most	NULL
5	NULL
'	NULL
major	NULL
transcription	NULL
initiation	NULL
site	NULL
in	NULL
monocytes	NULL
(	NULL
29	NULL
)	NULL
is	NULL
numbered	NULL
as	NULL
+1	NULL
.	NULL

Exons	NULL
and	NULL
introns	NULL
are	NULL
designated	NULL
for	NULL
the	NULL
placental	NULL
M-CSF	NULL
receptor	NULL
transcript	NULL
.	NULL

The	NULL
amino	NULL
acid	NULL
sequence	NULL
is	NULL
indicated	NULL
beneath	NULL
the	NULL
coding	NULL
DNA	NULL
sequence	NULL
.	NULL

The	NULL
initial	NULL
PCR	NULL
product	NULL
from	NULL
human	NULL
genomic	NULL
DNA	NULL
includes	NULL
the	NULL
M-CSF	NULL
receptor	NULL
sequence	NULL
from	NULL
bp	NULL
-416	NULL
to	NULL
+124	NULL
and	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
pXP2	NULL
to	NULL
construct	NULL
p540M-CSF-R-luc	NULL
.	NULL

The	NULL
construct	NULL
pM-CSF-R-luc	NULL
contains	NULL
the	NULL
M-CSF	NULL
receptor	NULL
upstream	NULL
sequence	NULL
from	NULL
bp	NULL
-416	NULL
to	NULL
+71	NULL
.	NULL

Potential	NULL
PU.1	NULL
binding	NULL
sites	NULL
based	NULL
on	NULL
consensus	NULL
sequence	NULL
analysis	NULL
(	NULL
29	NULL
)	NULL
are	NULL
marked	NULL
with	NULL
single	NULL
underlines	NULL
.	NULL

The	NULL
actual	NULL
PU.1	NULL
binding	NULL
site	NULL
detected	NULL
by	NULL
DNase	NULL
I	NULL
footprinting	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
and	NULL
by	NULL
gel	NULL
shift	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
double	NULL
underline	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

Human	NULL
monoblastic	NULL
U937	NULL
cells	NULL
(	NULL
ATCC	NULL
CRL	NULL
1593	NULL
;	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

and	NULL
T-lymphoblastic	NULL
REX	NULL
cells	NULL
(	NULL
provided	NULL
by	NULL
James	NULL
Griffin	NULL
,	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
HyClone	NULL
,	NULL
Logan	NULL
,	NULL
Utah	NULL
)	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

Human	NULL
promonocytic	NULL
THP-1	NULL
cells	NULL
(	NULL
ATCC	NULL
TIB	NULL
202	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
GIBCO	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
HyClone	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
(	NULL
GIBCO	NULL
)	NULL
,	NULL
and	NULL
2	NULL
x	NULL
10~Â°	NULL
M	NULL
2-mercaptoethanol	NULL
.	NULL

The	NULL
human	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
(	NULL
provided	NULL
by	NULL
H.	NULL
W.	NULL
L.	NULL
Ziegler-Heitbrock	NULL
)	NULL
were	NULL
propagated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Human	NULL
cervical	NULL
carcinoma	NULL
HeLa	NULL
cells	NULL
(	NULL
ATCC	NULL
CCL	NULL
2	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
GIBCO	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
newborn	NULL
calf	NULL
serum	NULL
(	NULL
GIBCO	NULL
)	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

Nuclear	NULL
run-on	NULL
transcription	NULL
assay	NULL
.	NULL

Nuclear	NULL
run-on	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Slot	NULL
blots	NULL
were	NULL
prepared	NULL
with	NULL
the	NULL
following	NULL
DNA	NULL
probes	NULL
:	NULL
the	NULL
plasmid	NULL
pBR322	NULL
,	NULL
a	NULL
2-kb	NULL
Pstl	NULL
fragment	NULL
of	NULL
the	NULL
chicken	NULL
actin	NULL
cDNA	NULL
in	NULL
pBR322	NULL
(	NULL
4	NULL
)	NULL
,	NULL
a	NULL
1.3-kb	NULL
fragment	NULL
containing	NULL
the	NULL
full	NULL
length	NULL
rat	NULL
glyceraldehyde-3-phosphate-dehydrogenase	NULL
cloned	NULL
in	NULL
the	NULL
PstI	NULL
site	NULL
of	NULL
pUC18	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
a	NULL
4-kb	NULL
EcoRI	NULL
fragment	NULL
containing	NULL
human	NULL
M-CSF	NULL
receptor	NULL
cDNA	NULL
in	NULL
pGEM	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
human	NULL
M-CSF	NULL
receptor	NULL
monocytic	NULL
promoter	NULL
.	NULL

The	NULL
sequence	NULL
5	NULL
'	NULL
of	NULL
exon	NULL
2	NULL
of	NULL
the	NULL
human	NULL
M-CSF	NULL
receptor	NULL
gene	NULL
was	NULL
amplified	NULL
and	NULL
cloned	NULL
from	NULL
HindIII-di-gested	NULL
human	NULL
genomic	NULL
DNA	NULL
by	NULL
PCR	NULL
based	NULL
on	NULL
the	NULL
published	NULL
sequence	NULL
(	NULL
29	NULL
)	NULL
with	NULL
primer	NULL
A	NULL
,	NULL
5-CGGGATCCAGATATG	NULL
CATTACTTTGGAGATTCCAAGG-3	NULL
'	NULL
,	NULL
and	NULL
primer	NULL
B	NULL
,	NULL
5'-GGGGTACCCCTCGGTGGGGAAGTGGCA-3	NULL
'	NULL
.	NULL

This	NULL
PCR	NULL
fragment	NULL
was	NULL
sequenced	NULL
and	NULL
found	NULL
to	NULL
be	NULL
identical	NULL
with	NULL
the	NULL
published	NULL
genomic	NULL
sequence	NULL
.	NULL

The	NULL
synthesized	NULL
fragment	NULL
is	NULL
540	NULL
bp	NULL
long	NULL
,	NULL
extending	NULL
at	NULL
its	NULL
3	NULL
'	NULL
end	NULL
to	NULL
within	NULL
3	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

With	NULL
the	NULL
most	NULL
5Â°	NULL
major	NULL
transcription	NULL
start	NULL
site	NULL
in	NULL
monocytic	NULL
cells	NULL
designated	NULL
as	NULL
position	NULL
+1	NULL
,	NULL
this	NULL
fragment	NULL
represents	NULL
bp	NULL
-416	NULL
to	NULL
+124	NULL
of	NULL
the	NULL
5	NULL
'	NULL
upstream	NULL
M-CSF	NULL
receptor	NULL
sequence	NULL
and	NULL
contains	NULL
178	NULL
bp	NULL
of	NULL
exon	NULL
2	NULL
(	NULL
29	NULL
)	NULL
.	NULL

The	NULL
PCR	NULL
fragment	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
and	NULL
KpnI	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
vector	NULL
pXP2	NULL
(	NULL
19	NULL
)	NULL
.	NULL

This	NULL
construct	NULL
is	NULL
referred	NULL
to	NULL
as	NULL
p540M-CSF-R-luc	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Transient	NULL
transfections	NULL
.	NULL

U937	NULL
,	NULL
Mono	NULL
Mac	NULL
6	NULL
,	NULL
and	NULL
REX	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
at	NULL
960	NULL
wF	NULL
and	NULL
300	NULL
,	NULL
230	NULL
,	NULL
and	NULL
280	NULL
V	NULL
,	NULL
respectively	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
at	NULL
960	NULL
wF	NULL
and	NULL
150	NULL
V.	NULL
The	NULL
detailed	NULL
transfection	NULL
procedures	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
5	NULL
h	NULL
posttransfection	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
,	NULL
and	NULL
luciferase	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
growth	NULL
hormone	NULL
expressed	NULL
from	NULL
2	NULL
pg	NULL
of	NULL
cotransfected	NULL
plasmid	NULL
containing	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter	NULL
directing	NULL
human	NULL
growth	NULL
hormone	NULL
gene	NULL
expression	NULL
(	NULL
RSV-hGH	NULL
)	NULL
,	NULL
and	NULL
data	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
light	NULL
units	NULL
per	NULL
nanogram	NULL
of	NULL
growth	NULL
hormone	NULL
.	NULL

Growth	NULL
hormone	NULL
concentrations	NULL
were	NULL
measured	NULL
by	NULL
radioimmunoassay	NULL
(	NULL
Nicol	NULL
's	NULL
Insti-tute	NULL
,	NULL
San	NULL
Juan	NULL
Capistrano	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
grown	NULL
to	NULL
a	NULL
concentration	NULL
of	NULL
6	NULL
x	NULL
10Â°/ml	NULL
and	NULL
harvested	NULL
for	NULL
nuclear	NULL
protein	NULL
extraction	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Approximately	NULL
15	NULL
mg	NULL
of	NULL
nuclear	NULL
protein	NULL
was	NULL
prepared	NULL
from	NULL
10Â°	NULL
cells	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
.	NULL

For	NULL
DNase	NULL
I	NULL
footprinting	NULL
assay	NULL
,	NULL
a	NULL
540-bp	NULL
DNA	NULL
fragment	NULL
extending	NULL
from	NULL
bp	NULL
-416	NULL
to	NULL
+124	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
and	NULL
Xhol	NULL
to	NULL
release	NULL
the	NULL
promoter	NULL
fragment	NULL
from	NULL
the	NULL
vector	NULL
pXP2	NULL
and	NULL
was	NULL
*P	NULL
labeled	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
44	NULL
)	NULL
.	NULL

PU.1	NULL
protein	NULL
was	NULL
in	NULL
vitro	NULL
translated	NULL
from	NULL
plasmid	NULL
p25.1	NULL
(	NULL
15	NULL
)	NULL
with	NULL
the	NULL
TnT	NULL
T7	NULL
coupled	NULL
reticulocyte	NULL
lysate	NULL
system	NULL
(	NULL
L4610	NULL
;	NULL
Vor	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
Promega	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocols	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Ten	NULL
microliters	NULL
of	NULL
unprogrammed	NULL
reticulocyte	NULL
lysate	NULL
or	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
or	NULL
90	NULL
pug	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
U937	NULL
cells	NULL
was	NULL
incubated	NULL
with	NULL
radiolabeled	NULL
DNA	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
4	NULL
ug	NULL
of	NULL
double-stranded	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
a	NULL
total	NULL
of	NULL
20	NULL
ul	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
[	NULL
HEPES	NULL
]	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
30	NULL
mM	NULL
KCl	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.4	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
12	NULL
%	NULL
glycerol	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
allowed	NULL
to	NULL
proceed	NULL
for	NULL
30	NULL
min	NULL
at	NULL
0Â°C	NULL
.	NULL

EMSA	NULL
.	NULL

P-labeled	NULL
double-stranded	NULL
oligonucleotides	NULL
for	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
conditions	NULL
were	NULL
identical	NULL
to	NULL
those	NULL
for	NULL
DNase	NULL
I	NULL
footprinting	NULL
,	NULL
except	NULL
for	NULL
the	NULL
addition	NULL
of	NULL
1	NULL
g	NULL
of	NULL
double-stranded	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

Reactions	NULL
were	NULL
electrophoresed	NULL
at	NULL
10	NULL
V/cm	NULL
on	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
bisacrylamide/acrylamide	NULL
ratio	NULL
=	NULL
1:29	NULL
)	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
(	NULL
45	NULL
mM	NULL
Tris-borate	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
at	NULL
4Â°C	NULL
.	NULL

For	NULL
supershift	NULL
experiments	NULL
,	NULL
a	NULL
1-pl	NULL
portion	NULL
of	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
raised	NULL
against	NULL
PU.1	NULL
was	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extract	NULL
and	NULL
preincu-bated	NULL
for	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
probe	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
serum	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
13-amino-acid	NULL
peptide	NULL
of	NULL
PU.1	NULL
(	NULL
amino	NULL
acids	NULL
33	NULL
to	NULL
45	NULL
of	NULL
the	NULL
mouse	NULL
PU.1	NULL
protein	NULL
[	NULL
15	NULL
]	NULL
)	NULL
and	NULL
supershifts	NULL
the	NULL
full-length	NULL
human	NULL
PU.1	NULL
protein	NULL
(	NULL
22	NULL
)	NULL
but	NULL
not	NULL
the	NULL
related	NULL
family	NULL
member	NULL
Spi-B	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Methylation	NULL
interference	NULL
analysis	NULL
.	NULL

Methylation	NULL
interference	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
3	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
probe	NULL
was	NULL
labeled	NULL
on	NULL
the	NULL
5Â°	NULL
end	NULL
of	NULL
the	NULL
noncoding-strand	NULL
oligonucleotide	NULL
TCGAGCTGATCCTCTITTCTITTCCCC	NULL
TTTTAGCTAGG	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
.	NULL

The	NULL
wild-type	NULL
M-CSF	NULL
receptor	NULL
promoter-luciferase	NULL
construct	NULL
p40M-CSF-R-luec	NULL
was	NULL
digested	NULL
with	NULL
Sacl	NULL
and	NULL
religated	NULL
to	NULL
delete	NULL
a	NULL
65-bp	NULL
fragment	NULL
and	NULL
construct	NULL
pM-CSF-R-luc	NULL
,	NULL
which	NULL
includes	NULL
-416	NULL
to	NULL
+71	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
region	NULL
.	NULL

The	NULL
-416-to-+124	NULL
and	NULL
-416-to-+71	NULL
fragments	NULL
had	NULL
identical	NULL
promoter	NULL
activities	NULL
when	NULL
p540M-CSF-R-luec	NULL
and	NULL
pM-CSF-R-luc	NULL
were	NULL
used	NULL
in	NULL
transient	NULL
transfection	NULL
experiments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
PU.1	NULL
site	NULL
at	NULL
bp	NULL
-40	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
were	NULL
generated	NULL
with	NULL
oligonucleotides	NULL
carrying	NULL
point	NULL
mutations	NULL
(	NULL
43	NULL
)	NULL
.	NULL

The	NULL
mutated	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
fragment	NULL
was	NULL
generated	NULL
by	NULL
PCR	NULL
.	NULL

Plasmid	NULL
p540M-CSF-R-luc	NULL
was	NULL
used	NULL
as	NULL
a	NULL
template	NULL
with	NULL
primer	NULL
A	NULL
(	NULL
shown	NULL
above	NULL
)	NULL
and	NULL
primer	NULL
C	NULL
(	NULL
5-GGGGTACCGATCCCTTITAGCTAGG-3	NULL
``	NULL
)	NULL
to	NULL
generate	NULL
PCR	NULL
fragment	NULL
1	NULL
and	NULL
with	NULL
primer	NULL
B	NULL
(	NULL
shown	NULL
above	NULL
)	NULL
and	NULL
primer	NULL
D	NULL
to	NULL
generate	NULL
PCR	NULL
fragment	NULL
2	NULL
.	NULL

PCR	NULL
fragment	NULL
1	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
and	NULL
KpnI	NULL
.	NULL

PCR	NULL
fragment	NULL
2	NULL
was	NULL
digested	NULL
with	NULL
KpnI	NULL
and	NULL
Sacl	NULL
.	NULL

Both	NULL
digested	NULL
PCR	NULL
fragments	NULL
were	NULL
ligated	NULL
with	NULL
BamHI-	NULL
and	NULL
Sacl-digested	NULL
vector	NULL
pXP2	NULL
to	NULL
construct	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-luc	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
mutant	NULL
construct	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
dideoxy	NULL
chain	NULL
termination	NULL
method	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
mutated	NULL
construct	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-luec	NULL
changed	NULL
the	NULL
sequence	NULL
GAAGAAGAG	NULL
at	NULL
bp	NULL
-45	NULL
to	NULL
-37	NULL
to	NULL
ATCGGTA	NULL
CC	NULL
.	NULL

Transactivation	NULL
of	NULL
promoter	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
method	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
2	NULL
)	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
,	NULL
with	NULL
and	NULL
without	NULL
1	NULL
pg	NULL
of	NULL
the	NULL
PU.1	NULL
expression	NULL
vector	NULL
PUpECE	NULL
(	NULL
15	NULL
)	NULL
,	NULL
with	NULL
0.25	NULL
ug	NULL
of	NULL
RSV-hGH	NULL
plasmid	NULL
,	NULL
and	NULL
with	NULL
sonicated	NULL
double-stranded	NULL
salmon	NULL
sperm	NULL
DNA	NULL
to	NULL
a	NULL
total	NULL
of	NULL
20	NULL
ug	NULL
of	NULL
DNA	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

PU.1	NULL
DIRECTS	NULL
M-CSF	NULL
RECEPTOR	NULL
EXPRESSION	NULL
375	NULL
REX	NULL
THP	NULL
M-CSF	NULL
R	NULL
Â«	NULL
Â«	NULL
mamine	NULL
nese	NULL
Actin	NULL
l	NULL
GAPDH	NULL
e	NULL
pBR322	NULL
&	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Tissue-specific	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Nuclear	NULL
run-on	NULL
transcription	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
nuclei	NULL
from	NULL
REX	NULL
(	NULL
T-cell	NULL
)	NULL
and	NULL
THP-1	NULL
(	NULL
mono-cytic	NULL
)	NULL
cells	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Nascent	NULL
radiolabeled	NULL
transcripts	NULL
were	NULL
hybridized	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
containing	NULL
a	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
indicated	NULL
cDNA	NULL
probes	NULL
.	NULL

RESULTS	NULL
The	NULL
M-CSF	NULL
receptor	NULL
is	NULL
specifically	NULL
transcribed	NULL
in	NULL
monocytic	NULL
cell	NULL
lines	NULL
.	NULL

Previous	NULL
investigators	NULL
have	NULL
demonstrated	NULL
M-CSF	NULL
receptor	NULL
transcriptional	NULL
activity	NULL
in	NULL
monocytic	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HL-60	NULL
,	NULL
but	NULL
posttranscriptional	NULL
mechanisms	NULL
played	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
the	NULL
accumulation	NULL
of	NULL
stable	NULL
M-CSF	NULL
receptor	NULL
RNA	NULL
following	NULL
monocytic	NULL
differentiation	NULL
with	NULL
tetradecanoyl	NULL
phorbol	NULL
acetate	NULL
(	NULL
41	NULL
)	NULL
.	NULL

These	NULL
results	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
tissue	NULL
specificity	NULL
of	NULL
M-CSF	NULL
receptor	NULL
RNA	NULL
expression	NULL
was	NULL
not	NULL
mediated	NULL
by	NULL
the	NULL
promoter	NULL
.	NULL

In	NULL
order	NULL
to	NULL
demonstrate	NULL
that	NULL
transcriptional	NULL
mechanisms	NULL
play	NULL
a	NULL
role	NULL
in	NULL
monocyte-specific	NULL
expression	NULL
,	NULL
we	NULL
compared	NULL
transcriptional	NULL
activities	NULL
detected	NULL
by	NULL
nuclear	NULL
run-on	NULL
assays	NULL
in	NULL
monocytic	NULL
(	NULL
THP-1	NULL
)	NULL
lines	NULL
with	NULL
those	NULL
in	NULL
nonmonocytic	NULL
(	NULL
REX	NULL
T-cell	NULL
)	NULL
lines	NULL
.	NULL

As	NULL
demonstrated	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
M-CSF	NULL
receptor	NULL
transcriptional	NULL
activity	NULL
was	NULL
detected	NULL
only	NULL
in	NULL
the	NULL
monocytic	NULL
cell	NULL
line	NULL
(	NULL
THP-1	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
promoter	NULL
was	NULL
at	NULL
least	NULL
partly	NULL
responsible	NULL
for	NULL
monocyte-specific	NULL
expression	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
activity	NULL
with	NULL
THP-1	NULL
cells	NULL
,	NULL
we	NULL
detected	NULL
run-on	NULL
activity	NULL
in	NULL
the	NULL
promonocytic	NULL
U937	NULL
cell	NULL
line	NULL
which	NULL
was	NULL
also	NULL
significantly	NULL
greater	NULL
than	NULL
that	NULL
seen	NULL
in	NULL
Rex	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
is	NULL
tissue	NULL
specific	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
region	NULL
5Â°	NULL
of	NULL
exon	NULL
2	NULL
for	NULL
monocytic	NULL
promoter	NULL
activity	NULL
,	NULL
a	NULL
DNA	NULL
fragment	NULL
spanning	NULL
from	NULL
-416	NULL
to	NULL
+124	NULL
of	NULL
the	NULL
human	NULL
M-CSF	NULL
receptor	NULL
gene	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
luciferase	NULL
reporter	NULL
vector	NULL
pXP2	NULL
to	NULL
form	NULL
p540M-CSF-R-luc	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Promoter	NULL
activities	NULL
were	NULL
monitored	NULL
by	NULL
luciferase	NULL
assays	NULL
after	NULL
transfection	NULL
into	NULL
the	NULL
human	NULL
promonocytic	NULL
U937	NULL
and	NULL
Mono	NULL
Mac	NULL
6	NULL
cell	NULL
lines	NULL
and	NULL
compared	NULL
with	NULL
those	NULL
following	NULL
transfection	NULL
of	NULL
the	NULL
human	NULL
nonmyeloid	NULL
cell	NULL
lines	NULL
REX	NULL
(	NULL
early	NULL
T-cell	NULL
)	NULL
and	NULL
HeLa	NULL
(	NULL
cervical	NULL
carcinoma	NULL
)	NULL
.	NULL

All	NULL
luciferase	NULL
values	NULL
were	NULL
corrected	NULL
for	NULL
transfection	NULL
efficiency	NULL
by	NULL
cotransfection	NULL
of	NULL
RSV-hGH	NULL
.	NULL

In	NULL
promonocytic	NULL
cells	NULL
,	NULL
the	NULL
M-CSF	NULL
receptor	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
demonstrated	NULL
very	NULL
strong	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
luciferase	NULL
activity	NULL
of	NULL
p540M-CSF-R-luec	NULL
was	NULL
100-	NULL
to	NULL
300-fold	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
the	NULL
pXP2	NULL
promoterless	NULL
con-struct	NULL
.	NULL

Comparative	NULL
analysis	NULL
revealed	NULL
that	NULL
this	NULL
promoter	NULL
functions	NULL
25-	NULL
to	NULL
100-fold	NULL
more	NULL
efficiently	NULL
in	NULL
promonocytic	NULL
cells	NULL
than	NULL
in	NULL
nonmyeloid	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrated	NULL
that	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
376	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

416	NULL
â¬	NULL
p540M-CSF-R-lue	NULL
pxXP2	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bror	NULL
.	NULL

16320	NULL
uas	NULL
?	NULL

E	NULL
Mono-Mac6	NULL
I	NULL
nex	NULL
M	NULL
Hels	NULL
I	NULL
I	NULL
U	NULL
I	NULL
U	NULL
20000	NULL
40000	NULL
80000	NULL
80000	NULL
100000	NULL
Promoter	NULL
Activity	NULL
(	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Tissue	NULL
specificity	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
in	NULL
transient	NULL
transfection	NULL
.	NULL

p540M-CSF-R-luc	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
promoterless	NULL
pXP2	NULL
vector	NULL
,	NULL
was	NULL
transfected	NULL
into	NULL
M-CSF	NULL
receptor-expressing	NULL
U937	NULL
and	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
and	NULL
into	NULL
M-CSF	NULL
receptor-negative	NULL
REX	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

One-fifth	NULL
of	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
luminescence	NULL
5	NULL
h	NULL
later	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
by	NULL
cotransfecting	NULL
RSV-hGH	NULL
,	NULL
and	NULL
relative	NULL
light	NULL
units	NULL
were	NULL
normalized	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
amount	NULL
of	NULL
growth	NULL
hormone	NULL
released	NULL
into	NULL
the	NULL
culture	NULL
medium	NULL
.	NULL

The	NULL
numbers	NULL
are	NULL
the	NULL
means	NULL
for	NULL
three	NULL
to	NULL
four	NULL
separate	NULL
experiments	NULL
.	NULL

The	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
means	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

gene	NULL
(	NULL
bp	NULL
-416	NULL
to	NULL
+124	NULL
)	NULL
contains	NULL
strong	NULL
tissue-specific	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
macrophage-	NULL
and	NULL
B-cell-specific	NULL
factor	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
at	NULL
a	NULL
site	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
5Â°	NULL
monocytic	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

As	NULL
mentioned	NULL
above	NULL
,	NULL
PU.1	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
ets	NULL
transcription	NULL
factor	NULL
family	NULL
and	NULL
is	NULL
predominantly	NULL
expressed	NULL
in	NULL
macrophages	NULL
and	NULL
B	NULL
cells	NULL
.	NULL

If	NULL
PU.1	NULL
is	NULL
a	NULL
major	NULL
determinant	NULL
of	NULL
the	NULL
myeloid	NULL
lineage	NULL
,	NULL
it	NULL
might	NULL
be	NULL
expected	NULL
to	NULL
regulate	NULL
a	NULL
number	NULL
of	NULL
myeloid-cell-specific	NULL
genes	NULL
,	NULL
including	NULL
the	NULL
M-CSF	NULL
receptor	NULL
,	NULL
a	NULL
lineage-specific	NULL
growth	NULL
factor	NULL
receptor	NULL
required	NULL
for	NULL
monocytic	NULL
development	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
used	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
protein	NULL
in	NULL
a	NULL
DNase	NULL
I	NULL
footprinting	NULL
assay	NULL
with	NULL
the	NULL
monocytic	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
fragment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
results	NULL
demonstrated	NULL
that	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
protein	NULL
specifically	NULL
protected	NULL
a	NULL
purine-rich	NULL
site	NULL
extending	NULL
from	NULL
bp	NULL
-33	NULL
to	NULL
-51	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

This	NULL
purine-rich	NULL
site	NULL
was	NULL
also	NULL
protected	NULL
with	NULL
nuclear	NULL
protein	NULL
extracts	NULL
from	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
U	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
whether	NULL
PU.1	NULL
is	NULL
the	NULL
factor	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
myeloid	NULL
cells	NULL
which	NULL
interacts	NULL
with	NULL
this	NULL
site	NULL
,	NULL
a	NULL
gel	NULL
shift	NULL
experiment	NULL
with	NULL
a	NULL
double-stranded	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
bp	NULL
-30	NULL
to	NULL
-59	NULL
was	NULL
performed	NULL
,	NULL
with	NULL
the	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
.	NULL

The	NULL
U937	NULL
nuclear	NULL
extract	NULL
gave	NULL
a	NULL
major	NULL
shifted	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
that	NULL
had	NULL
the	NULL
same	NULL
relative	NULL
migration	NULL
as	NULL
that	NULL
observed	NULL
with	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
protein	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

This	NULL
band	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
competition	NULL
with	NULL
unlabeled	NULL
self	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
a	NULL
known	NULL
PU.1-binding	NULL
oligonucleotide	NULL
from	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
enhancer	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
but	NULL
not	NULL
by	NULL
a	NULL
non-PU.1-binding	NULL
oligonucleotide	NULL
containing	NULL
an	NULL
Spl	NULL
site	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

When	NULL
a	NULL
polyclonal	NULL
antibody	NULL
against	NULL
an	NULL
N-terminal	NULL
PU.1	NULL
peptide	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
,	NULL
we	NULL
detected	NULL
a	NULL
loss	NULL
of	NULL
the	NULL
full-length	NULL
PU.1	NULL
band	NULL
and	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
supershifted	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

In	NULL
the	NULL
nuclear	NULL
extracts	NULL
,	NULL
several	NULL
specific	NULL
complexes	NULL
which	NULL
migrate	NULL
faster	NULL
than	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
protein	NULL
and	NULL
do	NULL
not	NULL
supershift	NULL
with	NULL
the	NULL
antibody	NULL
are	NULL
ob-served	NULL
;	NULL
these	NULL
have	NULL
been	NULL
observed	NULL
previously	NULL
(	NULL
9	NULL
,	NULL
22	NULL
,	NULL
34	NULL
)	NULL
and	NULL
represent	NULL
DNA-binding	NULL
complexes	NULL
formed	NULL
by	NULL
proteolytic	NULL
products	NULL
of	NULL
PU.1	NULL
.	NULL

(	NULL
The	NULL
PU.1	NULL
antiserum	NULL
recognizes	NULL
the	NULL
164	NULL
.I	NULL
~124	NULL
71	NULL
32	NULL
%	NULL
.	NULL

+14	NULL
+26	NULL
-	NULL
l	NULL
u	NULL
Â®	NULL
#	NULL
4	NULL
am	NULL
#	NULL
B	NULL
we	NULL
a	NULL
+4	NULL
â	NULL
)	NULL
-	NULL
.	NULL

#	NULL
an	NULL
am	NULL
=	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

DNase	NULL
I	NULL
protection	NULL
of	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
by	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
and	NULL
nuclear	NULL
protein	NULL
from	NULL
U937	NULL
cells	NULL
.	NULL

The	NULL
coding-strand-labeled	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
DNA	NULL
fragment	NULL
was	NULL
incubated	NULL
with	NULL
no	NULL
protein	NULL
(	NULL
lane	NULL
F	NULL
)	NULL
,	NULL
with	NULL
10	NULL
pl	NULL
of	NULL
unprogrammed	NULL
reticulocyte	NULL
lysate	NULL
(	NULL
lane	NULL
-	NULL
)	NULL
,	NULL
with	NULL
10	NULL
pl	NULL
of	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
protein	NULL
(	NULL
lane	NULL
+	NULL
)	NULL
,	NULL
or	NULL
with	NULL
90	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
U	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Lane	NULL
G/A	NULL
contains	NULL
the	NULL
probe	NULL
DNA	NULL
subjected	NULL
to	NULL
G+A-specific	NULL
Maxam-Gilbert	NULL
cleavage	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Numbers	NULL
at	NULL
the	NULL
left	NULL
are	NULL
numbers	NULL
of	NULL
nucleotides	NULL
upstream	NULL
(	NULL
-	NULL
)	NULL
or	NULL
downstream	NULL
(	NULL
+	NULL
)	NULL
of	NULL
the	NULL
5Â°	NULL
major	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
+1	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Sequences	NULL
protected	NULL
by	NULL
PU.1	NULL
from	NULL
DNase	NULL
I	NULL
digestion	NULL
are	NULL
indicated	NULL
with	NULL
a	NULL
bracket	NULL
.	NULL

377	NULL
PU.1	NULL
DIRECTS	NULL
M-CSF	NULL
RECEPTOR	NULL
EXPRESSION	NULL
Vor	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
A	NULL
B	NULL
C	NULL
C	NULL
Pua	NULL
U937	NULL
e	NULL
r	NULL
Abbreviation	NULL
Description	NULL
Sequence	NULL
a	NULL
p	NULL
~	NULL
soe	NULL
na	NULL
``	NULL
s	NULL
ros	NULL
R	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
-30	NULL
to	NULL
-59	NULL
TCGACCTAGCTAAAAGGGGAAGAAGAGGATCAGC	NULL
m	NULL
GGATCGATTTTCCCCTTCTTCTCCTAGTCGAGCT	NULL
6	NULL
.|	NULL
.	NULL

we	NULL
$	NULL
v	NULL
SV40	NULL
enhancer	NULL
PU.1	NULL
site	NULL
TGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTA	NULL
c	NULL
ACTTTATTGGAGACTTTCTCCTTGAACCAATCCAT	NULL
A	NULL
A	NULL
w	NULL
PU	NULL
I	NULL
--	NULL
s	NULL
CD1lb	NULL
Spl	NULL
site	NULL
TGCTCACTGAGCCTCCGCCCTCTTCcTrTe	NULL
hid	NULL
Wl	NULL
is	NULL
.	NULL

,	NULL
ACGAGTGACTCGGAGGCGGGAGAAGGAAAC	NULL
a+	NULL
$	NULL
a*	NULL
<	NULL
>	NULL
>	NULL
>	NULL
>	NULL
tn	NULL
<	NULL
i	NULL
Lane	NULL
:	NULL
(	NULL
1	NULL
2	NULL
3Â°4	NULL
7	NULL
%	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
PU.1	NULL
binding	NULL
to	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
cw	NULL
gel	NULL
mobility	NULL
shift	NULL
and	NULL
methylation	NULL
interference	NULL
analysis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
double-stranded	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
bp	NULL
-59	NULL
to	NULL
-30	NULL
was	NULL
end	NULL
labeled	NULL
with	NULL
and	NULL
incubated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
double-stranded	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
nuclear	NULL
protein	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
pl	NULL
of	NULL
unprogrammed	NULL
reticulocyte	NULL
lysate	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
2	NULL
l	NULL
of	NULL
reticulocyte	NULL
lysate	NULL
containing	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
5	NULL
pg	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
U937	NULL
cells	NULL
(	NULL
lanes	NULL
4	NULL
through	NULL
8	NULL
)	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
double-stranded	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
at	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
over	NULL
probe	NULL
oligonucleotide	NULL
:	NULL
M-CSF	NULL
receptor	NULL
bp	NULL
-59	NULL
to	NULL
-30	NULL
(	NULL
self	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
simian	NULL
virus	NULL
40	NULL
PU.1	NULL
binding	NULL
site	NULL
(	NULL
23	NULL
)	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
and	NULL
CD11b	NULL
Sp1	NULL
binding	NULL
site	NULL
(	NULL
3	NULL
)	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
8	NULL
,	NULL
anti-PU.1	NULL
antiserum	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

T	NULL
,	NULL
top	NULL
of	NULL
the	NULL
gel	NULL
;	NULL
PU.1	NULL
,	NULL
gel-shifted	NULL
complex	NULL
formed	NULL
with	NULL
full-length	NULL
in	NULL
vitro	NULL
PU.1	NULL
protein	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
;	NULL
S	NULL
,	NULL
supershifted	NULL
PU.1-DNA	NULL
complex	NULL
with	NULL
PU.1	NULL
antibody	NULL
;	NULL
F	NULL
,	NULL
unbound	NULL
free	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Abbreviations	NULL
,	NULL
names	NULL
,	NULL
and	NULL
sequences	NULL
of	NULL
oligonucleotides	NULL
used	NULL
in	NULL
the	NULL
gel	NULL
mobility	NULL
shift	NULL
analysis	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Methylation	NULL
interference	NULL
analysis	NULL
of	NULL
DNA	NULL
contact	NULL
points	NULL
of	NULL
PU.1	NULL
to	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
.	NULL

The	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
from	NULL
bp	NULL
-~59	NULL
to	NULL
-30	NULL
was	NULL
P	NULL
labeled	NULL
at	NULL
the	NULL
5Â°	NULL
end	NULL
of	NULL
the	NULL
noncoding	NULL
strand	NULL
and	NULL
methylated	NULL
by	NULL
treatment	NULL
with	NULL
limiting	NULL
quantities	NULL
of	NULL
dimethylsulfate	NULL
.	NULL

In	NULL
lane	NULL
F	NULL
,	NULL
free	NULL
DNA	NULL
from	NULL
the	NULL
EMSA	NULL
gel	NULL
was	NULL
subjected	NULL
to	NULL
piperidine-mediated	NULL
cleavage	NULL
of	NULL
methylated	NULL
G.	NULL
In	NULL
lane	NULL
S	NULL
,	NULL
DNA	NULL
from	NULL
supershifted	NULL
complex	NULL
of	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
bp	NULL
-30	NULL
to	NULL
-59	NULL
,	NULL
U937	NULL
nuclear	NULL
protein	NULL
,	NULL
and	NULL
PU.1	NULL
antibody	NULL
as	NULL
shown	NULL
in	NULL
panel	NULL
A	NULL
,	NULL
lane	NULL
8	NULL
,	NULL
was	NULL
subjected	NULL
to	NULL
piperidine-mediated	NULL
cleavage	NULL
of	NULL
methylated	NULL
G	NULL
residues	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
oligonucleotide	NULL
is	NULL
shown	NULL
on	NULL
the	NULL
left	NULL
.	NULL

The	NULL
solid	NULL
circles	NULL
indicate	NULL
the	NULL
direct	NULL
contacts	NULL
between	NULL
the	NULL
DNA	NULL
and	NULL
PU.1	NULL
.	NULL

378	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
TCGACCTAGCTAAAAGGGGAAGAAGAGGATCAGC	NULL
Wild	NULL
Type	NULL
Sequence	NULL
:	NULL
GGATCGATTTTCCCCTTCTTCTCCTAGTCGAGCT	NULL
Mutated	NULL
Sequence	NULL
:	NULL
TCGACCTAGCTAAAAGGGATCGGTACCGATCAGC	NULL
GGATCGATTTACCCTAGCCATGGCTAGTCGAGCT	NULL
B	NULL
Competitor	NULL
:	NULL
Protein	NULL
:	NULL
~	NULL
+	NULL
+	NULL
+	NULL
PU1	NULL
--	NULL
-	NULL
$	NULL
as	NULL
8	NULL
8	NULL
-	NULL
.	NULL

Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Mutation	NULL
at	NULL
PU.1	NULL
binding	NULL
site	NULL
eliminates	NULL
its	NULL
binding	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequences	NULL
of	NULL
wild-type	NULL
(	NULL
W	NULL
)	NULL
and	NULL
mutated	NULL
(	NULL
M	NULL
)	NULL
forms	NULL
of	NULL
bp	NULL
-59	NULL
to	NULL
-30	NULL
of	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
.	NULL

The	NULL
mutated	NULL
nucleotides	NULL
in	NULL
the	NULL
oligonucleotide	NULL
are	NULL
underlined	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Competition	NULL
analysis	NULL
of	NULL
the	NULL
PU.1	NULL
mutation	NULL
by	NULL
EMSA	NULL
.	NULL

The	NULL
double-stranded	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
bp	NULL
-59	NULL
to	NULL
-30	NULL
oligonucleotide	NULL
was	NULL
*Â°P	NULL
labeled	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
of	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
U937	NULL
cells	NULL
with	NULL
1	NULL
g	NULL
of	NULL
double-stranded	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

A	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
wild-type	NULL
(	NULL
W	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
M-CSF	NULL
receptor	NULL
PU.1-site-mutated	NULL
(	NULL
M	NULL
)	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
oligonucleotides	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

All	NULL
the	NULL
other	NULL
symbols	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5.	NULL
pM-CSF-R-luc	NULL
U937	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-lue	NULL
pxXP2	NULL
pM-CSF-R-luc	NULL
REX	NULL
|	NULL
pm-csr-R	NULL
(	NULL
m4o	NULL
}	NULL
-uc	NULL
L	NULL
pxP2	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bor	NULL
.	NULL

amino	NULL
terminus	NULL
of	NULL
PU.1	NULL
,	NULL
and	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
is	NULL
located	NULL
at	NULL
the	NULL
carboxyl	NULL
terminus	NULL
.	NULL
)	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
PU.1	NULL
specifically	NULL
binds	NULL
to	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
at	NULL
a	NULL
site	NULL
between	NULL
bp	NULL
-30	NULL
and	NULL
-59	NULL
.	NULL

The	NULL
observed	NULL
complex	NULL
which	NULL
migrates	NULL
more	NULL
slowly	NULL
than	NULL
the	NULL
full-length	NULL
PU.1	NULL
complex	NULL
is	NULL
likely	NULL
a	NULL
nonspecific	NULL
band	NULL
,	NULL
since	NULL
it	NULL
can	NULL
not	NULL
be	NULL
eliminated	NULL
by	NULL
excess	NULL
self	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

To	NULL
define	NULL
the	NULL
residues	NULL
on	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
contacted	NULL
by	NULL
the	NULL
PU.1	NULL
protein	NULL
,	NULL
methylation	NULL
interference	NULL
assays	NULL
were	NULL
performed	NULL
,	NULL
with	NULL
the	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5C	NULL
.	NULL

The	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
four	NULL
G	NULL
residues	NULL
at	NULL
bp	NULL
-48	NULL
to	NULL
-45	NULL
directly	NULL
contact	NULL
the	NULL
PU.1	NULL
protein	NULL
.	NULL

A	NULL
mutation	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
which	NULL
abolishes	NULL
PU.1	NULL
binding	NULL
decreases	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

To	NULL
verify	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
for	NULL
monocyte-specific	NULL
M-CSF	NULL
receptor	NULL
expression	NULL
,	NULL
the	NULL
site	NULL
was	NULL
mutated	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

An	NULL
oligonucleotide	NULL
with	NULL
a	NULL
mutated	NULL
PU.1	NULL
site	NULL
could	NULL
not	NULL
inhibit	NULL
PU.1	NULL
binding	NULL
to	NULL
the	NULL
wild-type	NULL
region	NULL
from	NULL
bp	NULL
-59	NULL
to	NULL
-30	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
same	NULL
PU.1	NULL
mutant-site	NULL
oligonucleotide	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
or	NULL
PU.1	NULL
from	NULL
U937	NULL
nuclear	NULL
extracts	NULL
in	NULL
gel	NULL
shift	NULL
assays	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
was	NULL
then	NULL
introduced	NULL
into	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter-luciferase	NULL
construct	NULL
to	NULL
form	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-luc	NULL
.	NULL

Transient	NULL
transfection	NULL
experiments	NULL
comparing	NULL
the	NULL
wild-type	NULL
plasmid	NULL
pM-CSF-R-luc	NULL
and	NULL
the	NULL
mutant	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-luc	NULL
demonstrated	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
reduced	NULL
promoter	NULL
activity	NULL
to	NULL
16	NULL
%	NULL
of	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
promoter	NULL
in	NULL
promonocytic	NULL
U937	NULL
cells	NULL
and	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
low-level	NULL
promoter	NULL
activity	NULL
in	NULL
the	NULL
REX	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
does	NULL
not	NULL
express	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
promoter	NULL
at	NULL
a	NULL
functionally	NULL
critical	NULL
site	NULL
.	NULL

PU.1	NULL
activates	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
in	NULL
nonmonocytic	NULL
cells	NULL
.	NULL

To	NULL
demonstrate	NULL
that	NULL
PU.1	NULL
is	NULL
critical	NULL
for	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
activity	NULL
,	NULL
cotransactivation	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
nonmyeloid	NULL
HeLa	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
lacks	NULL
endogenous	NULL
PU.1	NULL
activity	NULL
(	NULL
15	NULL
,	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

The	NULL
promoterless	NULL
luciferase	NULL
expression	NULL
vector	NULL
pXP2	NULL
,	NULL
the	NULL
wild-type	NULL
M-CSF	NULL
receptor	NULL
luciferase	NULL
construct	NULL
pM-CSF-R-luc	NULL
,	NULL
and	NULL
the	NULL
Mean	NULL
Value	NULL
Activity	NULL
RLUng	NULL
(	NULL
%	NULL
)	NULL
119,834	NULL
100	NULL
19,523	NULL
16.3	NULL
969	NULL
0.8	NULL
4096	NULL
3.4	NULL
3974	NULL
3.3	NULL
310	NULL
0.3	NULL
T	NULL
t	NULL
80000	NULL
120000	NULL
160000	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units	NULL
(	NULL
RLU	NULL
)	NULL
ing	NULL
Growth	NULL
Hormone	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
significantly	NULL
reduces	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
wild-type	NULL
M-CSF	NULL
receptor	NULL
promoter-luciferase	NULL
gene	NULL
construct	NULL
(	NULL
pM-CSF-R-luc	NULL
)	NULL
,	NULL
the	NULL
PU.1-site-mutated	NULL
construct	NULL
[	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-luc	NULL
]	NULL
,	NULL
and	NULL
the	NULL
promoterless	NULL
pXP2	NULL
luciferase	NULL
construct	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
the	NULL
human	NULL
promonocytic	NULL
cell	NULL
line	NULL
U937	NULL
and	NULL
early	NULL
T-cell	NULL
line	NULL
REX	NULL
.	NULL

The	NULL
averages	NULL
and	NULL
standard	NULL
errors	NULL
were	NULL
generated	NULL
from	NULL
four	NULL
separate	NULL
experiments	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
.	NULL

Luciferase	NULL
activities	NULL
were	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
plasmid	NULL
RSV-hGH	NULL
.	NULL

The	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
means	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

Vor	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
PU.1	NULL
DIRECTS	NULL
M-CSF	NULL
RECEPTOR	NULL
EXPRESSION	NULL
379	NULL
Mean	NULL
Value	NULL
Fold	NULL
RLUIng	NULL
Increase	NULL
a	NULL
19	NULL
+2	NULL
pxP2	NULL
I	NULL
:	NULL
*	NULL
1.0	NULL
#	NULL
$	NULL
19	NULL
+	NULL
0	NULL
pM-CSF-R-lue	NULL
I	NULL
:	NULL
~	NULL
294	NULL
4	NULL
65	NULL
5.1	NULL
+	NULL
1493	NULL
+	NULL
208	NULL
=	NULL
396	NULL
+	NULL
74	NULL
0.84	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-lue	NULL
l	NULL
:	NULL
+	NULL
331	NULL
4	NULL
71	NULL
0	NULL
10210	NULL
2000	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units	NULL
(	NULL
RLUy/ng	NULL
Growth	NULL
Hormone	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

PU.1	NULL
stimulates	NULL
transcription	NULL
from	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
in	NULL
transactivation	NULL
assays	NULL
.	NULL

PU.l-negative	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
Ca	NULL
,	NULL
(	NULL
PO	NULL
,	NULL
)	NULL
;	NULL
precipitation	NULL
method	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
promoterless	NULL
luciferase	NULL
construct	NULL
pXP2	NULL
,	NULL
the	NULL
wild-type	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
construct	NULL
(	NULL
pM-CSF-R-luc	NULL
)	NULL
,	NULL
or	NULL
the	NULL
PU.1	NULL
mutant	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
construct	NULL
[	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-luc	NULL
]	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
cotransfected	NULL
with	NULL
or	NULL
without	NULL
the	NULL
PU.1	NULL
expression	NULL
vector	NULL
PUpECE	NULL
.	NULL

Luciferase	NULL
activities	NULL
were	NULL
measured	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

PU.1	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
represents	NULL
the	NULL
luciferase	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cotransfected	NULL
PU.1	NULL
divided	NULL
by	NULL
that	NULL
obtained	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PU.1	NULL
.	NULL

Luciferase	NULL
activities	NULL
are	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
plasmid	NULL
RSV-hGH	NULL
.	NULL

The	NULL
data	NULL
are	NULL
the	NULL
means	NULL
for	NULL
three	NULL
to	NULL
five	NULL
experiments	NULL
.	NULL

The	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
means	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

PU.1-binding-site-mutated	NULL
M-CSF	NULL
receptor	NULL
luciferase	NULL
construct	NULL
pM-CSF-R	NULL
(	NULL
m40	NULL
)	NULL
-luec	NULL
were	NULL
transfected	NULL
separately	NULL
into	NULL
HeLa	NULL
cells	NULL
with	NULL
and	NULL
without	NULL
cotransfection	NULL
of	NULL
the	NULL
PU.1	NULL
expression	NULL
plasmid	NULL
PUpECE	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

All	NULL
luciferase	NULL
values	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
level	NULL
of	NULL
growth	NULL
hormone	NULL
production	NULL
to	NULL
correct	NULL
for	NULL
any	NULL
variation	NULL
in	NULL
transfection	NULL
efficiency	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
PU.1	NULL
expression	NULL
,	NULL
wild-type	NULL
and	NULL
PU.1-binding-site-mutated	NULL
M-CSF	NULL
receptor	NULL
promoters	NULL
had	NULL
the	NULL
same	NULL
level	NULL
of	NULL
promoter	NULL
activity	NULL
in	NULL
HeLa	NULL
cells	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
the	NULL
level	NULL
of	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
was	NULL
lower	NULL
when	NULL
the	NULL
PU.1	NULL
site	NULL
was	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
cotransfected	NULL
PU.1	NULL
,	NULL
the	NULL
wild-type	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
activity	NULL
increased	NULL
fivefold	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
PU.1-binding-site-mutated	NULL
promoter	NULL
showed	NULL
no	NULL
increase	NULL
.	NULL

When	NULL
a	NULL
retinoic	NULL
acid	NULL
receptor	NULL
B	NULL
expression	NULL
plasmid	NULL
(	NULL
1	NULL
)	NULL
was	NULL
cotransfected	NULL
with	NULL
the	NULL
wild-type	NULL
M-CSF	NULL
receptor	NULL
luciferase	NULL
construct	NULL
,	NULL
there	NULL
was	NULL
no	NULL
effect	NULL
on	NULL
promoter	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
and	NULL
the	NULL
results	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
assays	NULL
described	NULL
above	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
and	NULL
6	NULL
)	NULL
demonstrate	NULL
that	NULL
the	NULL
interaction	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
and	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
is	NULL
essential	NULL
for	NULL
monocytic	NULL
promoter	NULL
activity	NULL
.	NULL

DISCUSSION	NULL
M-CSF	NULL
receptor	NULL
expression	NULL
is	NULL
limited	NULL
to	NULL
the	NULL
monocyte/	NULL
macrophage	NULL
lineage	NULL
in	NULL
the	NULL
hematopoietic	NULL
system	NULL
.	NULL

The	NULL
level	NULL
of	NULL
M-CSF	NULL
receptor	NULL
RNA	NULL
increases	NULL
specifically	NULL
when	NULL
human	NULL
CD34+	NULL
multipotential	NULL
progenitors	NULL
are	NULL
induced	NULL
to	NULL
differentiate	NULL
into	NULL
early	NULL
myeloid	NULL
cells	NULL
with	NULL
granulocyte	NULL
M-CSF	NULL
but	NULL
not	NULL
when	NULL
the	NULL
same	NULL
progenitor	NULL
population	NULL
is	NULL
induced	NULL
toward	NULL
erythroid	NULL
differentiation	NULL
with	NULL
erythropoietin	NULL
(	NULL
40a	NULL
)	NULL
.	NULL

Others	NULL
have	NULL
shown	NULL
that	NULL
when	NULL
committed	NULL
promonocytic	NULL
cell	NULL
lines	NULL
like	NULL
HL-60	NULL
are	NULL
induced	NULL
with	NULL
tetradecanoyl	NULL
phorbol	NULL
acetate	NULL
to	NULL
differentiate	NULL
into	NULL
nondividing	NULL
macrophage-like	NULL
cells	NULL
,	NULL
M-CSF	NULL
receptor	NULL
RNA	NULL
increases	NULL
significantly	NULL
but	NULL
transcription	NULL
rates	NULL
do	NULL
not	NULL
,	NULL
suggesting	NULL
that	NULL
receptor	NULL
RNA	NULL
is	NULL
upregulated	NULL
by	NULL
posttranscriptional	NULL
mechanisms	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Recent	NULL
results	NULL
have	NULL
suggested	NULL
a	NULL
transcriptional	NULL
upregulation	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
in	NULL
HL-60	NULL
cells	NULL
induced	NULL
to	NULL
differentiate	NULL
with	NULL
retinoic	NULL
acid	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
M-CSF	NULL
receptor	NULL
transcription	NULL
can	NULL
be	NULL
detected	NULL
by	NULL
run-on	NULL
analysis	NULL
in	NULL
monocytic	NULL
lines	NULL
but	NULL
not	NULL
in	NULL
nonmonocytic	NULL
(	NULL
T-cell	NULL
)	NULL
lines	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
promoter	NULL
is	NULL
important	NULL
for	NULL
lineage-specific	NULL
expression	NULL
.	NULL

Others	NULL
have	NULL
previously	NULL
isolated	NULL
the	NULL
placental	NULL
and	NULL
monocytic	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
those	NULL
experiments	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
strong	NULL
simian	NULL
virus	NULL
40	NULL
enhancer	NULL
was	NULL
necessary	NULL
to	NULL
demonstrate	NULL
monocyte-specific	NULL
expression	NULL
,	NULL
making	NULL
a	NULL
detailed	NULL
analysis	NULL
of	NULL
the	NULL
functional	NULL
elements	NULL
of	NULL
the	NULL
promoter	NULL
difficult	NULL
.	NULL

Using	NULL
optimized	NULL
transfection	NULL
protocols	NULL
,	NULL
we	NULL
have	NULL
been	NULL
able	NULL
to	NULL
demonstrate	NULL
that	NULL
the	NULL
monocyte	NULL
promoter	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
heterologous	NULL
enhancer	NULL
has	NULL
significant	NULL
tissue-specific	NULL
activity	NULL
.	NULL

Sequence	NULL
analysis	NULL
of	NULL
the	NULL
promoter	NULL
suggested	NULL
the	NULL
presence	NULL
of	NULL
three	NULL
potential	NULL
binding	NULL
sites	NULL
for	NULL
the	NULL
PU.1	NULL
transcription	NULL
factor	NULL
(	NULL
29	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
as	NULL
was	NULL
the	NULL
case	NULL
for	NULL
the	NULL
myeloid-cell-specific	NULL
CD11b	NULL
promoter	NULL
(	NULL
22	NULL
)	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
demonstrate	NULL
PU.1	NULL
binding	NULL
to	NULL
those	NULL
sites	NULL
.	NULL

Instead	NULL
,	NULL
PU.1	NULL
protein	NULL
,	NULL
whether	NULL
in	NULL
vitro	NULL
translated	NULL
or	NULL
isolated	NULL
from	NULL
nuclear	NULL
extracts	NULL
,	NULL
bound	NULL
to	NULL
a	NULL
distinct	NULL
purine-rich	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
)	NULL
which	NULL
does	NULL
not	NULL
contain	NULL
this	NULL
specific	NULL
sequence	NULL
.	NULL

However	NULL
,	NULL
methylation	NULL
interference	NULL
analysis	NULL
indicates	NULL
that	NULL
four	NULL
G	NULL
residues	NULL
in	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
directly	NULL
interact	NULL
with	NULL
PU.1	NULL
,	NULL
a	NULL
pattern	NULL
quite	NULL
similar	NULL
to	NULL
the	NULL
three	NULL
G	NULL
residues	NULL
identified	NULL
as	NULL
contact	NULL
points	NULL
in	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
PU.1	NULL
binding	NULL
site	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Further	NULL
analysis	NULL
with	NULL
additional	NULL
point	NULL
mutants	NULL
of	NULL
the	NULL
CD11b	NULL
and	NULL
M-CSF	NULL
receptor	NULL
binding	NULL
sites	NULL
will	NULL
be	NULL
necessary	NULL
to	NULL
determine	NULL
which	NULL
additional	NULL
bases	NULL
are	NULL
important	NULL
for	NULL
PU.1	NULL
binding	NULL
.	NULL

When	NULL
this	NULL
PU.1	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
was	NULL
mutated	NULL
,	NULL
the	NULL
promoter	NULL
activity	NULL
decreased	NULL
dramatically	NULL
only	NULL
in	NULL
monocytic	NULL
cells	NULL
(	NULL
U937	NULL
)	NULL
and	NULL
remained	NULL
unchanged	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
both	NULL
REX	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

When	NULL
380	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

PU.1	NULL
is	NULL
expressed	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
it	NULL
can	NULL
transactivate	NULL
a	NULL
cotransfected	NULL
wild-type	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
but	NULL
not	NULL
the	NULL
PU.1-binding-site-mutated	NULL
promoter	NULL
.	NULL

All	NULL
of	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
PU.1	NULL
binds	NULL
to	NULL
a	NULL
site	NULL
other	NULL
than	NULL
5'-GAGGAA-3	NULL
'	NULL
and	NULL
directs	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
activity	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

As	NULL
is	NULL
the	NULL
case	NULL
for	NULL
CD11b	NULL
(	NULL
22	NULL
)	NULL
,	NULL
PU.1	NULL
binds	NULL
to	NULL
a	NULL
site	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
transcriptional	NULL
start	NULL
site	NULL
in	NULL
a	NULL
promoter	NULL
which	NULL
lacks	NULL
a	NULL
consensus	NULL
TATAA	NULL
box	NULL
or	NULL
initiator	NULL
sequence	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
PU.1	NULL
binds	NULL
specifically	NULL
to	NULL
TATAA-binding	NULL
protein	NULL
in	NULL
vitro	NULL
(	NULL
12	NULL
)	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
part	NULL
of	NULL
the	NULL
function	NULL
of	NULL
PU.1	NULL
in	NULL
these	NULL
promoters	NULL
is	NULL
to	NULL
recruit	NULL
TFIID	NULL
and	NULL
subsequently	NULL
the	NULL
other	NULL
components	NULL
of	NULL
the	NULL
basal	NULL
transcriptional	NULL
machinery	NULL
to	NULL
a	NULL
promoter	NULL
lacking	NULL
TATAA	NULL
,	NULL
the	NULL
TATAA-binding	NULL
protein	NULL
binding	NULL
site	NULL
.	NULL

Whether	NULL
this	NULL
will	NULL
be	NULL
a	NULL
common	NULL
mechanism	NULL
in	NULL
other	NULL
monocytic	NULL
genes	NULL
regulated	NULL
by	NULL
PU.1	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

While	NULL
many	NULL
of	NULL
the	NULL
ets	NULL
family	NULL
transcription	NULL
factors	NULL
interact	NULL
with	NULL
another	NULL
protein	NULL
to	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
DNA	NULL
(	NULL
6	NULL
,	NULL
13	NULL
,	NULL
38	NULL
)	NULL
and	NULL
PU.1	NULL
itself	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
the	NULL
B-cell	NULL
factor	NULL
NF-EMS	NULL
to	NULL
activate	NULL
the	NULL
immunoglobulin	NULL
Â«	NULL
3	NULL
'	NULL
enhancer	NULL
(	NULL
24	NULL
)	NULL
,	NULL
our	NULL
gel	NULL
shift	NULL
experiments	NULL
with	NULL
the	NULL
PU.1	NULL
site	NULL
of	NULL
CD11b	NULL
(	NULL
22	NULL
)	NULL
and	NULL
with	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
suggest	NULL
that	NULL
PU.1	NULL
binds	NULL
these	NULL
two	NULL
monocyte	NULL
promoters	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
stable	NULL
complex	NULL
with	NULL
another	NULL
protein	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
case	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
detect	NULL
any	NULL
significant	NULL
effect	NULL
of	NULL
a	NULL
serine-to-alanine	NULL
mutation	NULL
at	NULL
position	NULL
148	NULL
(	NULL
or	NULL
at	NULL
positions	NULL
41	NULL
,	NULL
45	NULL
,	NULL
132	NULL
,	NULL
and	NULL
133	NULL
)	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
M.	NULL
Klemsz	NULL
and	NULL
R.	NULL
Maki	NULL
)	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
PU.1	NULL
expression	NULL
constructs	NULL
to	NULL
transactivate	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Whether	NULL
these	NULL
differences	NULL
reflect	NULL
an	NULL
inherent	NULL
distinction	NULL
between	NULL
the	NULL
ways	NULL
in	NULL
which	NULL
PU.1	NULL
works	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
in	NULL
myeloid	NULL
cells	NULL
or	NULL
whether	NULL
it	NULL
reflects	NULL
a	NULL
distinct	NULL
mechanism	NULL
of	NULL
PU.1	NULL
action	NULL
in	NULL
these	NULL
TATAA-less	NULL
myeloid	NULL
genes	NULL
remains	NULL
unknown	NULL
.	NULL

While	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
PU.1	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
monocytic	NULL
expression	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
,	NULL
the	NULL
fact	NULL
that	NULL
PU.1	NULL
plays	NULL
a	NULL
similarly	NULL
important	NULL
role	NULL
in	NULL
a	NULL
gene	NULL
expressed	NULL
in	NULL
both	NULL
monocytes	NULL
and	NULL
neutrophils	NULL
(	NULL
CD11b	NULL
)	NULL
and	NULL
in	NULL
B-cell	NULL
gene	NULL
expression	NULL
suggests	NULL
that	NULL
other	NULL
factors	NULL
may	NULL
play	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
M-CSF	NULL
receptor	NULL
monocyte-specific	NULL
expression	NULL
.	NULL

In	NULL
vitro	NULL
DNase	NULL
I	NULL
footprinting	NULL
demonstrates	NULL
that	NULL
,	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
CD11b	NULL
,	NULL
there	NULL
is	NULL
an	NULL
Spl	NULL
binding	NULL
site	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
in	NULL
the	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
(	NULL
44a	NULL
)	NULL
.	NULL

Whether	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
for	NULL
CD11b	NULL
(	NULL
3	NULL
)	NULL
,	NULL
Spl	NULL
binds	NULL
in	NULL
a	NULL
myeloid-cell-specific	NULL
fashion	NULL
in	NULL
vivo	NULL
to	NULL
activate	NULL
the	NULL
M-CSF	NULL
receptor	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
by	NULL
in	NULL
vivo	NULL
footprinting	NULL
and	NULL
transfection	NULL
experiments	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
have	NULL
detected	NULL
two	NULL
sites	NULL
upstream	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
which	NULL
are	NULL
strongly	NULL
protected	NULL
in	NULL
in	NULL
vitro	NULL
DNase	NULL
I	NULL
footprinting	NULL
analysis	NULL
with	NULL
extracts	NULL
from	NULL
myeloid	NULL
cells	NULL
but	NULL
not	NULL
from	NULL
HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
identity	NULL
and	NULL
functional	NULL
significance	NULL
of	NULL
these	NULL
myeloid-cell-specific	NULL
binding	NULL
activities	NULL
remain	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

The	NULL
monocyte-specific	NULL
expression	NULL
of	NULL
M-CSF	NULL
receptor	NULL
may	NULL
require	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
monocyte-	NULL
and	NULL
B-cell-specific	NULL
PU.1	NULL
factor	NULL
and	NULL
other	NULL
tissue-specific	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
,	NULL
including	NULL
factors	NULL
which	NULL
interact	NULL
with	NULL
DNA	NULL
elements	NULL
outside	NULL
the	NULL
540-bp	NULL
promoter	NULL
region	NULL
tested	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
a	NULL
functionally	NULL
significant	NULL
PU.1	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
CD11ib	NULL
and	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
demonstrate	NULL
that	NULL
at	NULL
least	NULL
two	NULL
important	NULL
monocytic	NULL
genes	NULL
are	NULL
regulated	NULL
by	NULL
PU.1	NULL
.	NULL

PU.1	NULL
mRNA	NULL
,	NULL
like	NULL
that	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
,	NULL
is	NULL
strongly	NULL
and	NULL
specifically	NULL
upregulated	NULL
as	NULL
CD34+	NULL
progenitors	NULL
are	NULL
specifically	NULL
differentiated	NULL
into	NULL
myeloid	NULL
cells	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

(	NULL
40a	NULL
)	NULL
.	NULL

PU.1	NULL
upregulation	NULL
precedes	NULL
that	NULL
of	NULL
CD11b	NULL
and	NULL
the	NULL
M-CSF	NULL
receptor	NULL
by	NULL
days	NULL
,	NULL
suggesting	NULL
that	NULL
PU.1	NULL
upregulation	NULL
may	NULL
be	NULL
an	NULL
important	NULL
early	NULL
event	NULL
in	NULL
myeloid	NULL
commitment	NULL
and	NULL
differentiation	NULL
.	NULL

Inactivation	NULL
or	NULL
disruption	NULL
of	NULL
the	NULL
PU.1	NULL
gene	NULL
will	NULL
help	NULL
to	NULL
determine	NULL
whether	NULL
PU.1	NULL
expression	NULL
and	NULL
upregulation	NULL
is	NULL
necessary	NULL
for	NULL
myeloid	NULL
development	NULL
,	NULL
and	NULL
further	NULL
analysis	NULL
of	NULL
monocytic	NULL
promoters	NULL
such	NULL
as	NULL
the	NULL
M-CSF	NULL
receptor	NULL
should	NULL
lead	NULL
to	NULL
the	NULL
identification	NULL
of	NULL
other	NULL
factors	NULL
which	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
this	NULL
lineage	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
wish	NULL
to	NULL
thank	NULL
Richard	NULL
Maki	NULL
for	NULL
the	NULL
PU.1	NULL
antisera	NULL
and	NULL
PU.1	NULL
expression	NULL
constructs	NULL
,	NULL
Tom	NULL
Look	NULL
and	NULL
Mark	NULL
Roberts	NULL
for	NULL
M-CSF	NULL
receptor	NULL
DNA	NULL
constructs	NULL
,	NULL
H.	NULL
W.	NULL
Loms	NULL
Ziegler-Hettbrock	NULL
for	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
,	NULL
Pierre	NULL
Chambon	NULL
for	NULL
the	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
B	NULL
expression	NULL
construct	NULL
,	NULL
Suzan	NULL
Dziennis	NULL
for	NULL
assistance	NULL
in	NULL
PCR	NULL
,	NULL
and	NULL
Tim	NULL
Burn	NULL
and	NULL
Anne	NULL
Satterthwaite	NULL
for	NULL
encouragement	NULL
and	NULL
discus-sions	NULL
.	NULL

D.G.T	NULL
.	NULL

is	NULL
a	NULL
scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
PHS	NULL
grant	NULL
CA41456	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Brand	NULL
,	NULL
N.	NULL
,	NULL
M.	NULL
Petkovich	NULL
,	NULL
A.	NULL
Krust	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
H.	NULL
de	NULL
The	NULL
,	NULL
A.	NULL
Marchio	NULL
,	NULL
P.	NULL
Tiollais	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
second	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
332:850-853	NULL
.	NULL

2	NULL
.	NULL

Chen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
H.	NULL
Okayama	NULL
.	NULL

1988	NULL
.	NULL

Calcium	NULL
phosphate-mediated	NULL
gene	NULL
transfer	NULL
:	NULL
a	NULL
highly	NULL
efficient	NULL
transfection	NULL
system	NULL
for	NULL
stably	NULL
transforming	NULL
cells	NULL
with	NULL
plasmid	NULL
DNA	NULL
.	NULL

BioTechniques	NULL
6:632-638	NULL
.	NULL

3	NULL
.	NULL

Chen	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
H.	NULL
L.	NULL
Pahl	NULL
,	NULL
R.	NULL
J.	NULL
Scheibe	NULL
,	NULL
D.-E.	NULL
Zhang	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
Spl	NULL
transcription	NULL
factor	NULL
binds	NULL
the	NULL
CD11b	NULL
promoter	NULL
specifically	NULL
in	NULL
myeloid	NULL
cells	NULL
in	NULL
vivo	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
myeloid-specific	NULL
promoter	NULL
activity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:8230-8239	NULL
.	NULL

4	NULL
.	NULL

Cleveland	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
M.	NULL
A.	NULL
Lopata	NULL
,	NULL
R.	NULL
J.	NULL
MacDonald	NULL
,	NULL
N.	NULL
J.	NULL
Cowan	NULL
,	NULL
W.	NULL
J.	NULL
Rutter	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
Kirschner	NULL
.	NULL

1980	NULL
.	NULL

Number	NULL
and	NULL
evolutionary	NULL
conservation	NULL
of	NULL
alpha-	NULL
and	NULL
beta-tubulin	NULL
and	NULL
cytoplasmic	NULL
beta-	NULL
and	NULL
gamma-actin	NULL
genes	NULL
using	NULL
specific	NULL
cloned	NULL
cDNA	NULL
probes	NULL
.	NULL

Cell	NULL
20:95-105	NULL
.	NULL

5	NULL
.	NULL

Coussens	NULL
,	NULL
L.	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
D.	NULL
Smith	NULL
,	NULL
E.	NULL
Chen	NULL
,	NULL
R.	NULL
L.	NULL
Mitchell	NULL
,	NULL
C.	NULL
M.	NULL
Isacke	NULL
,	NULL
I.	NULL
M.	NULL
Verma	NULL
,	NULL
and	NULL
A.	NULL
Ullrich	NULL
.	NULL

1986	NULL
.	NULL

Structural	NULL
alteration	NULL
of	NULL
viral	NULL
homologue	NULL
of	NULL
receptor	NULL
proto-oncogene	NULL
fms	NULL
at	NULL
carboxyl	NULL
terminus	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
320:277-280	NULL
.	NULL

6	NULL
.	NULL

Dalton	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Treisman	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
SAP-1	NULL
,	NULL
a	NULL
protein	NULL
recruited	NULL
by	NULL
serum	NULL
response	NULL
factor	NULL
to	NULL
the	NULL
c-fos	NULL
serum	NULL
response	NULL
element	NULL
.	NULL

Cell	NULL
68:597-612	NULL
.	NULL

7	NULL
.	NULL

Ford	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
L.	NULL
E.	NULL
Healy	NULL
,	NULL
C.	NULL
A.	NULL
Bennett	NULL
,	NULL
E.	NULL
Navarro	NULL
,	NULL
E.	NULL
Spooncer	NULL
,	NULL
and	NULL
M.	NULL
F.	NULL
Greaves	NULL
.	NULL

1992	NULL
.	NULL

Multilineage	NULL
phenotypes	NULL
of	NULL
interleukin-3-dependent	NULL
progenitor	NULL
cells	NULL
.	NULL

Blood	NULL
79:1962-1971	NULL
.	NULL

8	NULL
.	NULL

Fort	NULL
,	NULL
P.	NULL
,	NULL
L.	NULL
Marty	NULL
,	NULL
M.	NULL
Piechaczyk	NULL
,	NULL
S.	NULL
el	NULL
Sabrouty	NULL
,	NULL
C.	NULL
Dani	NULL
,	NULL
P.	NULL
Jeanteur	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Blanchard	NULL
.	NULL

1985	NULL
.	NULL

Various	NULL
rat	NULL
adult	NULL
tissues	NULL
express	NULL
only	NULL
one	NULL
major	NULL
mRNA	NULL
species	NULL
from	NULL
the	NULL
glyceraldehyde-3-phosphate-dehydrogenase	NULL
multigenic	NULL
family	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

13:1431-1434	NULL
.	NULL

9	NULL
.	NULL

Galson	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
J.	NULL
O.	NULL
Hensold	NULL
,	NULL
T.	NULL
R.	NULL
Bishop	NULL
,	NULL
M.	NULL
Schalling	NULL
,	NULL
A.	NULL
D.	NULL
D'Andrea	NULL
,	NULL
C.	NULL
Jones	NULL
,	NULL
P.	NULL
E.	NULL
Auron	NULL
,	NULL
and	NULL
D.	NULL
E.	NULL
Housman	NULL
.	NULL

1993	NULL
.	NULL

Mouse	NULL
B-globin	NULL
DNA-binding	NULL
protein	NULL
B1	NULL
is	NULL
identical	NULL
to	NULL
a	NULL
proto-oncogene	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
Spi-1/PU.1	NULL
,	NULL
and	NULL
is	NULL
restricted	NULL
in	NULL
expression	NULL
to	NULL
hematopoietic	NULL
cells	NULL
and	NULL
the	NULL
testis	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:2929-2941	NULL
.	NULL

10	NULL
.	NULL

Gisselbrecht	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Fichelson	NULL
,	NULL
B.	NULL
Sola	NULL
,	NULL
D.	NULL
Bordereaux	NULL
,	NULL
A.	NULL
Hampe	NULL
,	NULL
C.	NULL
Andre	NULL
,	NULL
F.	NULL
Galibert	NULL
,	NULL
and	NULL
P.	NULL
Tambourin	NULL
.	NULL

1987	NULL
.	NULL

Frequent	NULL
c-fims	NULL
activation	NULL
by	NULL
proviral	NULL
insertion	NULL
in	NULL
mouse	NULL
myeloblastic	NULL
leukaemias	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
329:259-261	NULL
.	NULL

11	NULL
.	NULL

Gliniak	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Rohrschneider	NULL
.	NULL

1990	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
is	NULL
controlled	NULL
posttranscriptionally	NULL
by	NULL
the	NULL
dominant	NULL
actions	NULL
of	NULL
GM-CSF	NULL
or	NULL
multi-CSF	NULL
.	NULL

Cell	NULL
63:1073-1083	NULL
.	NULL

12	NULL
.	NULL

Hagemeier	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
J.	NULL
Bannister	NULL
,	NULL
A.	NULL
Cook	NULL
,	NULL
and	NULL
T.	NULL
Kouzarides	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
activation	NULL
domain	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
Vor	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29.	NULL
the	NULL
retinoblastoma	NULL
(	NULL
RB	NULL
)	NULL
protein	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
TFIID	NULL
in	NULL
vitro	NULL
:	NULL
RB	NULL
shows	NULL
sequence	NULL
similarity	NULL
to	NULL
TFIID	NULL
and	NULL
TFIIB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:1580-1584	NULL
.	NULL

Hipskind	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
V.	NULL
N.	NULL
Rao	NULL
,	NULL
C.	NULL
G.	NULL
Mueller	NULL
,	NULL
E.	NULL
S.	NULL
Reddy	NULL
,	NULL
and	NULL
A.	NULL
Nordheim	NULL
.	NULL

1991	NULL
.	NULL

Ets-related	NULL
protein	NULL
Elk-1	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
c-fos	NULL
regulatory	NULL
factor	NULL
pG2TCF	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
354:531-534	NULL
.	NULL

Hsu	NULL
,	NULL
H.-C.	NULL
,	NULL
K.	NULL
Yang	NULL
,	NULL
S.	NULL
Kharbanda	NULL
,	NULL
S.	NULL
Clinton	NULL
,	NULL
R.	NULL
Datta	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Stone	NULL
.	NULL

1993	NULL
.	NULL

All-trans	NULL
retinoic	NULL
acid	NULL
induces	NULL
monocyte	NULL
growth	NULL
factor	NULL
receptor	NULL
(	NULL
c-fms	NULL
)	NULL
gene	NULL
expression	NULL
in	NULL
HL60	NULL
leukemia	NULL
cells	NULL
.	NULL

Leukemia	NULL
(	NULL
Basingstoke	NULL
)	NULL
7:458-462	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113-124	NULL
.	NULL

Maxam	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Gilbert	NULL
.	NULL

1980	NULL
.	NULL

Sequencing	NULL
end-labeled	NULL
DNA	NULL
with	NULL
base-specific	NULL
chemical	NULL
cleavages	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

65:499-560	NULL
.	NULL

Moreau-Gachelin	NULL
,	NULL
F.	NULL
,	NULL
D.	NULL
Ray	NULL
,	NULL
M.	NULL
G.	NULL
Mattei	NULL
,	NULL
P.	NULL
Tambourin	NULL
,	NULL
and	NULL
A.	NULL
Tavitian	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
putative	NULL
oncogene	NULL
Spi-1	NULL
:	NULL
murine	NULL
chro-mosomal	NULL
localization	NULL
and	NULL
transcriptional	NULL
activation	NULL
in	NULL
murine	NULL
acute	NULL
erythroleukemias	NULL
.	NULL

Oncogene	NULL
4:1449-1456	NULL
.	NULL

Nienhuis	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
H.	NULL
F.	NULL
Bunn	NULL
,	NULL
P.	NULL
H.	NULL
Turner	NULL
,	NULL
T.	NULL
V.	NULL
Gopal	NULL
,	NULL
W.	NULL
G.	NULL
Nash	NULL
,	NULL
S.	NULL
J.	NULL
O'Brien	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Sherr	NULL
.	NULL

1985	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
human	NULL
c-fms	NULL
proto-oncogene	NULL
in	NULL
hematopoietic	NULL
cells	NULL
and	NULL
its	NULL
deletion	NULL
in	NULL
the	NULL
5q-	NULL
syndrome	NULL
.	NULL

Cell	NULL
42:421-428	NULL
.	NULL

Nordeen	NULL
,	NULL
S.	NULL
K.	NULL
1988	NULL
.	NULL

Luciferase	NULL
reporter	NULL
gene	NULL
vectors	NULL
for	NULL
analysis	NULL
of	NULL
promoters	NULL
and	NULL
enhancers	NULL
.	NULL

BioTechniques	NULL
6:454-458	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
T.	NULL
C.	NULL
Burn	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1991	NULL
.	NULL

Optimization	NULL
of	NULL
transient	NULL
transfection	NULL
into	NULL
human	NULL
myeloid	NULL
cell	NULL
lines	NULL
using	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

(	NULL
New	NULL
York	NULL
)	NULL
19:1038-1041	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
A.	NULL
G.	NULL
Rosmarin	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11lb	NULL
promoter	NULL
.	NULL

Blood	NULL
79	NULL
:	NULL
865-870	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
R.	NULL
J.	NULL
Scheibe	NULL
,	NULL
D.-E.	NULL
Zhang	NULL
,	NULL
H.	NULL
M.	NULL
Chen	NULL
,	NULL
D.	NULL
L.	NULL
Galson	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
proto-oncogene	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:5014-5020.	NULL
.	NULL

Petterson	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
purine-rich	NULL
DNA	NULL
sequence	NULL
motif	NULL
present	NULL
in	NULL
SV40	NULL
and	NULL
lymphotropic	NULL
papovavirus	NULL
binds	NULL
a	NULL
Iymphoid-specific	NULL
factor	NULL
and	NULL
contributes	NULL
to	NULL
enhancer	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

1:962-972	NULL
.	NULL

Pongubala	NULL
,	NULL
J.	NULL
M.	NULL
R.	NULL
,	NULL
S.	NULL
Nagulapalli	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Atchison	NULL
.	NULL

1992	NULL
.	NULL

PU.1	NULL
recruits	NULL
a	NULL
second	NULL
nuclear	NULL
factor	NULL
to	NULL
a	NULL
site	NULL
important	NULL
for	NULL
immunoglobulin	NULL
k	NULL
3	NULL
'	NULL
enhancer	NULL
activity	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:368-378.	NULL
.	NULL

Pongubala	NULL
,	NULL
J.	NULL
M.	NULL
R.	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
S.	NULL
Nagulapalli	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Atchison	NULL
.	NULL

1993	NULL
.	NULL

Effect	NULL
of	NULL
PU.1	NULL
phosphorylation	NULL
on	NULL
interaction	NULL
with	NULL
NF-EMS	NULL
and	NULL
transcriptional	NULL
activation	NULL
.	NULL

Science	NULL
259:1622-1625	NULL
.	NULL

Ray	NULL
,	NULL
D.	NULL
,	NULL
R.	NULL
Bosselut	NULL
,	NULL
J.	NULL
Ghysdael	NULL
,	NULL
M.-G.	NULL
Mattei	NULL
,	NULL
A.	NULL
Tavitian	NULL
,	NULL
and	NULL
F.	NULL
Moreau-Gachelin	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
Spi-B	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
related	NULL
to	NULL
the	NULL
putative	NULL
oncoprotein	NULL
Spi-l1/	NULL
PU.1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4297-4304	NULL
.	NULL

Ridge	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
M.	NULL
Worwood	NULL
,	NULL
D.	NULL
Oscier	NULL
,	NULL
A.	NULL
Jacobs	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Padua	NULL
.	NULL

1990	NULL
.	NULL

FMS	NULL
mutations	NULL
in	NULL
myelodysplastic	NULL
,	NULL
leukemic	NULL
,	NULL
and	NULL
normal	NULL
subjects	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:1377-1380.	NULL
.	NULL

Roberts	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
A.	NULL
T.	NULL
Look	NULL
,	NULL
M.	NULL
F.	NULL
Roussel	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Sherr	NULL
.	NULL

1988	NULL
.	NULL

Tandem	NULL
linkage	NULL
of	NULL
human	NULL
CSF-1	NULL
receptor	NULL
(	NULL
c-fms	NULL
)	NULL
and	NULL
PDGF	NULL
receptor	NULL
genes	NULL
.	NULL

Cell	NULL
55:655-661	NULL
.	NULL

Roberts	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
L.	NULL
H.	NULL
Shapiro	NULL
,	NULL
R.	NULL
A.	NULL
Ashmun	NULL
,	NULL
and	NULL
A.	NULL
T.	NULL
Look	NULL
.	NULL

1992	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
human	NULL
colony-stimulating	NULL
factor-1	NULL
30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

PU.1	NULL
DIRECTS	NULL
M-CSF	NULL
RECEPTOR	NULL
EXPRESSION	NULL
381	NULL
receptor	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
separate	NULL
tissue-specific	NULL
promoters	NULL
.	NULL

Blood	NULL
79:586-593	NULL
.	NULL

Roussel	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
J.	NULL
R.	NULL
Downing	NULL
,	NULL
C.	NULL
W.	NULL
Rettenmier	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Sherr	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
human	NULL
CSF-1	NULL
receptor	NULL
(	NULL
c-fms	NULL
proto-oncogene	NULL
product	NULL
)	NULL
activates	NULL
its	NULL
transforming	NULL
potential	NULL
.	NULL

Cell	NULL
5Â§5:979-988	NULL
.	NULL

Sanger	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
Nicklen	NULL
,	NULL
and	NULL
A.	NULL
R.	NULL
Coulson	NULL
.	NULL

1977	NULL
.	NULL

DNA	NULL
sequencing	NULL
with	NULL
chain-terminating	NULL
inhibitors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
74:5463-5467	NULL
.	NULL

Sariban	NULL
,	NULL
E.	NULL
,	NULL
K.	NULL
Imamura	NULL
,	NULL
M.	NULL
Sherman	NULL
,	NULL
V.	NULL
Rothwell	NULL
,	NULL
P.	NULL
Pantazis	NULL
,	NULL
and	NULL
D.	NULL
Kufe	NULL
.	NULL

1989	NULL
.	NULL

Downregulation	NULL
of	NULL
c-fms	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
treated	NULL
with	NULL
phorbol	NULL
esters	NULL
and	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
.	NULL

Blood	NULL
74:123-129	NULL
.	NULL

Satterthwaite	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
R.	NULL
Borson	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
gene	NULL
for	NULL
CD34	NULL
,	NULL
a	NULL
human	NULL
hematopoietic	NULL
stem	NULL
cell	NULL
antigen	NULL
,	NULL
in	NULL
KG-1	NULL
cells	NULL
.	NULL

Blood	NULL
75:2299-2304	NULL
.	NULL

Schuetze	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Paul	NULL
,	NULL
B.	NULL
C.	NULL
Gliniak	NULL
,	NULL
and	NULL
D.	NULL
Kabat	NULL
.	NULL

1992	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
PU.1	NULL
transcription	NULL
factor	NULL
in	NULL
controlling	NULL
differentiation	NULL
of	NULL
Friend	NULL
erythroleukemia	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:2967-2975	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

1990	NULL
.	NULL

Colony-stimulating	NULL
factor-1	NULL
receptor	NULL
.	NULL

Blood	NULL
75:1-12	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
C.	NULL
W.	NULL
Rettenmier	NULL
,	NULL
R.	NULL
Sacca	NULL
,	NULL
M.	NULL
F.	NULL
Roussel	NULL
,	NULL
A.	NULL
T.	NULL
Look	NULL
,	NULL
and	NULL
E.	NULL
R.	NULL
Stanley	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
c-fms	NULL
proto-oncogene	NULL
product	NULL
is	NULL
related	NULL
to	NULL
the	NULL
receptor	NULL
for	NULL
the	NULL
mononuclear	NULL
phago-cyte	NULL
growth	NULL
factor	NULL
,	NULL
CSF-1	NULL
.	NULL

Cell	NULL
41:665-676	NULL
.	NULL

Smale	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
``	NULL
initiator	NULL
``	NULL
as	NULL
a	NULL
transcription	NULL
control	NULL
element	NULL
.	NULL

Cell	NULL
57:103-113	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

Brown	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1991	NULL
.	NULL

Convergence	NULL
of	NULL
Ets-	NULL
and	NULL
notch-related	NULL
structural	NULL
motifs	NULL
in	NULL
a	NULL
heteromeric	NULL
DNA	NULL
binding	NULL
complex	NULL
.	NULL

Science	NULL
253:762-768	NULL
.	NULL

Tobal	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Pagliuca	NULL
,	NULL
B.	NULL
Bhatt	NULL
,	NULL
N.	NULL
Bailey	NULL
,	NULL
D.	NULL
M.	NULL
Layton	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Mufti	NULL
.	NULL

1990	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
human	NULL
FMS	NULL
gene	NULL
(	NULL
M-CSF	NULL
receptor	NULL
)	NULL
in	NULL
myelodysplastic	NULL
syndromes	NULL
and	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Leukemia	NULL
(	NULL
Basingstoke	NULL
)	NULL
4:486-489	NULL
.	NULL

Visvader	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1989	NULL
.	NULL

Differential	NULL
transcription	NULL
of	NULL
exon	NULL
1	NULL
of	NULL
the	NULL
human	NULL
c-fms	NULL
gene	NULL
in	NULL
placental	NULL
trophoblasts	NULL
and	NULL
monocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:1336-1341	NULL
.	NULL

40a.Voso	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
T.	NULL
C.	NULL
Burn	NULL
,	NULL
G.	NULL
Wilf	NULL
,	NULL
B.	NULL
Lim	NULL
,	NULL
G.	NULL
Leone	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

Tenen	NULL
.	NULL

Inhibition	NULL
of	NULL
hematopoiesis	NULL
by	NULL
competitive	NULL
binding	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
PU.1	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

Weber	NULL
,	NULL
B.	NULL
,	NULL
J.	NULL
Horiguchi	NULL
,	NULL
R.	NULL
Luebbers	NULL
,	NULL
M.	NULL
Sherman	NULL
,	NULL
and	NULL
D.	NULL
Kufe	NULL
.	NULL

1989	NULL
.	NULL

Posttranscriptional	NULL
stabilization	NULL
of	NULL
c-fms	NULL
mRNA	NULL
by	NULL
a	NULL
labile	NULL
protein	NULL
during	NULL
human	NULL
monocytic	NULL
differentiation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:769-775	NULL
.	NULL

Woolford	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
McAuliffe	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Rohrschneider	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
feline	NULL
c-fms	NULL
proto-oncogene	NULL
:	NULL
multiple	NULL
alterations	NULL
are	NULL
required	NULL
to	NULL
generate	NULL
a	NULL
fully	NULL
transformed	NULL
phenotype	NULL
.	NULL

Cell	NULL
55:965-977	NULL
.	NULL

Zaret	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
J.	NULL
K.	NULL
Liu	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
DiPersio	NULL
.	NULL

1990	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
reveals	NULL
a	NULL
liver	NULL
transcription	NULL
factor	NULL
essential	NULL
for	NULL
the	NULL
albumin	NULL
transcriptional	NULL
enhancer	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:5469-5473.	NULL
.	NULL

Zhang	NULL
,	NULL
D.-E.	NULL
,	NULL
P.	NULL
R.	NULL
Hoyt	NULL
,	NULL
and	NULL
J.	NULL
Papaconstantinou	NULL
.	NULL

1990	NULL
.	NULL

Localization	NULL
of	NULL
DNA	NULL
protein-binding	NULL
sites	NULL
in	NULL
the	NULL
proximal	NULL
and	NULL
distal	NULL
promoter	NULL
regions	NULL
of	NULL
the	NULL
mouse	NULL
alpha-fetoprotein	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:3382-3391	NULL
.	NULL

442a.Zhang	NULL
,	NULL
D.-E.	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

45	NULL
.	NULL

Ziegler-Heitbrock	NULL
,	NULL
H.	NULL
W.	NULL
L.	NULL
,	NULL
E.	NULL
Thiel	NULL
,	NULL
A.	NULL
Futterer	NULL
,	NULL
V.	NULL
Herzog	NULL
,	NULL
A.	NULL
Wirtz	NULL
,	NULL
and	NULL
G.	NULL
Riethmuller	NULL
.	NULL

1988	NULL
.	NULL

Establishment	NULL
of	NULL
a	NULL
human	NULL
cell	NULL
line	NULL
(	NULL
Mono	NULL
Mac	NULL
6	NULL
)	NULL
with	NULL
characteristics	NULL
of	NULL
mature	NULL
monocytes	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
41:456-461	NULL
.	NULL

